<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">65872</article-id><article-id pub-id-type="doi">10.7554/eLife.65872</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>HBO1-MLL interaction promotes AF4/ENL/P-TEFb-mediated leukemogenesis</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-215525"><name><surname>Takahashi</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215523"><name><surname>Kanai</surname><given-names>Akinori</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1555-6768</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215524"><name><surname>Okuda</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215522"><name><surname>Miyamoto</surname><given-names>Ryo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-241253"><name><surname>Komata</surname><given-names>Yosuke</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-220048"><name><surname>Kawamura</surname><given-names>Takeshi</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215526"><name><surname>Matsui</surname><given-names>Hirotaka</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215527"><name><surname>Inaba</surname><given-names>Toshiya</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-110196"><name><surname>Takaori-Kondo</surname><given-names>Akifumi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7678-4284</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-211712"><name><surname>Yokoyama</surname><given-names>Akihiko</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5639-8068</contrib-id><email>ayokoyam@ncc-tmc.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Tsuruoka Metabolomics Laboratory, National Cancer Center</institution><addr-line><named-content content-type="city">Tsuruoka</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution>Department of Hematology and Oncology, Kyoto University Graduate School of Medicine</institution><addr-line><named-content content-type="city">Kyoto</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution>Department of Molecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University</institution><addr-line><named-content content-type="city">Hiroshima</named-content></addr-line><country>Japan</country></aff><aff id="aff4"><label>4</label><institution>Isotope Science Center, The University of Tokyo</institution><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff><aff id="aff5"><label>5</label><institution>Department of Molecular Laboratory Medicine, Faculty of Life Sciences, Kumamoto University</institution><addr-line><named-content content-type="city">Kumamoto</named-content></addr-line><country>Japan</country></aff><aff id="aff6"><label>6</label><institution>Division of Hematological Malignancy, National Cancer Center Research Institute</institution><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shi</surname><given-names>Xiaobing</given-names></name><role>Reviewing Editor</role><aff><institution>Van Andel Institute</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Struhl</surname><given-names>Kevin</given-names></name><role>Senior Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>25</day><month>08</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e65872</elocation-id><history><date date-type="received" iso-8601-date="2020-12-17"><day>17</day><month>12</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-08-12"><day>12</day><month>08</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-01-08"><day>08</day><month>01</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.01.08.425834"/></event></pub-history><permissions><copyright-statement>© 2021, Takahashi et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Takahashi et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-65872-v1.pdf"/><abstract><p>Leukemic oncoproteins cause uncontrolled self-renewal of hematopoietic progenitors by aberrant gene activation, eventually causing leukemia. However, the molecular mechanism underlying aberrant gene activation remains elusive. Here, we showed that leukemic MLL fusion proteins associate with the HBO1 histone acetyltransferase (HAT) complex through their trithorax homology domain 2 (THD2) in various human cell lines. MLL proteins associated with the HBO1 complex through multiple contacts mediated mainly by the ING4/5 and PHF16 subunits in a chromatin-bound context where histone H3 lysine 4 tri-methylation marks were present. Of the many MLL fusions, MLL-ELL particularly depended on the THD2-mediated association with the HBO1 complex for leukemic transformation. The C-terminal portion of ELL provided a binding platform for multiple factors including AF4, EAF1, and p53. MLL-ELL activated gene expression in murine hematopoietic progenitors by loading an AF4/ENL/P-TEFb (AEP) complex onto the target promoters wherein the HBO1 complex promoted the association with AEP complex over EAF1 and p53. Moreover, the NUP98-HBO1 fusion protein exerted its oncogenic properties via interaction with MLL but not its intrinsic HAT activity. Thus, the interaction between the HBO1 complex and MLL is an important nexus in leukemic transformation, which may serve as a therapeutic target for drug development.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>MLL</kwd><kwd>HBO1</kwd><kwd>leukemia</kwd><kwd>epigenetic regulators</kwd><kwd>ENL</kwd><kwd>AF4</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>16H05337</award-id><principal-award-recipient><name><surname>Yokoyama</surname><given-names>Akihiko</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>19H03694</award-id><principal-award-recipient><name><surname>Yokoyama</surname><given-names>Akihiko</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005931</institution-id><institution>Yamagata Health Support Association</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Yokoyama</surname><given-names>Akihiko</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>the City of Tsuruoka</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Yokoyama</surname><given-names>Akihiko</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005968</institution-id><institution>Leukemia Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Yokoyama</surname><given-names>Akihiko</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002975</institution-id><institution>Dainippon Sumitomo Pharma Co., Ltd.</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Yokoyama</surname><given-names>Akihiko</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Interaction of the MLL and HBO1 complexes is a key nexus for leukemic transformation that can serve as a therapeutic target.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Mutated transcriptional regulators often cause uncontrolled self-renewal of immature hematopoietic precursors, which leads to aggressive leukemia. MLL (also known as KMT2A) is a transcriptional maintenance factor that upregulates homeobox (<italic>HOX</italic>) genes in development (<xref ref-type="bibr" rid="bib66">Yu et al., 1998</xref>). Chromosomal translocations generate fusion genes encoding various MLL fusion proteins with more than 80 different partners to induce leukemia (<xref ref-type="bibr" rid="bib29">Meyer et al., 2018</xref>). MLL fusion proteins cause uncontrolled self-renewal by constitutively activating various oncogenic genes (e.g., <italic>HOXA9</italic>, <italic>MEIS1</italic>), whose expression is normally restricted in immature precursors such as hematopoietic stem cells (HSCs) (<xref ref-type="bibr" rid="bib17">Krivtsov et al., 2006</xref>). However, the mechanisms by which MLL fusion proteins aberrantly activate the expression of HSC-specific genes remain elusive.</p><p>MLL fusion proteins form a complex with MENIN (<xref ref-type="bibr" rid="bib63">Yokoyama et al., 2005</xref>; <xref ref-type="bibr" rid="bib62">Yokoyama et al., 2004</xref>), which leads to further association with LEGDF (<xref ref-type="bibr" rid="bib65">Yokoyama and Cleary, 2008</xref>). MLL fusion proteins bind to their target chromatin through the CXXC domain of MLL, which specifically recognizes unmethylated CpGs, and the PWWP domain of LEDGF, which selectively binds to di/tri-methylated histone H3 lysine 36 (H3K36me2/3) (<xref ref-type="bibr" rid="bib4">Ayton et al., 2004</xref>; <xref ref-type="bibr" rid="bib5">Birke et al., 2002</xref>; <xref ref-type="bibr" rid="bib42">Pradeepa et al., 2012</xref>; <xref ref-type="bibr" rid="bib55">van Nuland et al., 2013</xref>). The CXXC and PWWP domains constitute the minimum targeting module (MTM) which can stably bind to the human MLL target gene promoters (e.g., <italic>HOXA9</italic>) (<xref ref-type="bibr" rid="bib36">Okuda et al., 2014</xref>). Because unmethylated CpGs and H3K36me2/3 marks are associated with transcriptional activation, MLL fusion proteins target a broad range of previously transcribed CpG-rich promoters. Although MLL fuses with a variety of partners, most MLL fusion-mediated leukemia cases are caused by the fusions with the AF4 family (e.g., AF4 also known as AFF1, AF5Q31 also known as AFF4) and ENL family (e.g., ENL also known as MLLT1, AF9 also known as MLLT3) (<xref ref-type="bibr" rid="bib29">Meyer et al., 2018</xref>). AF4 family proteins form a biochemically stable complex with ENL family proteins and the P-TEFb elongation factor (composed of CDK9 and CyclinT1/2), which we termed AEP complex (as in AF4 family/ENL family/P-TEFb complex) (<xref ref-type="bibr" rid="bib64">Yokoyama et al., 2010</xref>). AF4 family proteins recruit the SL1 complex (<xref ref-type="bibr" rid="bib37">Okuda et al., 2015</xref>), which is composed of TBP and the TAF1A/B/C/D subunits and is known to initiate ribosomal RNA transcription by RNA polymerase I (<xref ref-type="bibr" rid="bib11">Goodfellow and Zomerdijk, 2013</xref>). An artificial construct of MTM fused to the binding platform for SL1 activated the murine <italic>Hoxa9</italic> gene and transformed hematopoietic progenitors (HPCs) (<xref ref-type="bibr" rid="bib37">Okuda et al., 2015</xref>), indicating that the AF4 family protein activates RNA polymerase II (RNAP2)-dependent transcription, presumably by loading TBP onto the target promoters via SL1. However, why MLL fusion proteins preferentially use the AEP/SL1-mediated transcription pathway is unclear.</p><p>In this study, we identified the evolutionarily conserved trithorax homology domain 2 (THD2) of MLL (previously termed TRX2 domain) as a key structure required for aberrant self-renewal mediated by MLL fusion proteins. A subsequent proteomic approach identified the HBO1 (also known as KAT7 and MYST2) histone acetyltransferase (HAT) complex as an associating factor for THD2. HBO1 is a member of the MYST HAT family responsible for histone H3 lysine 14 acetylation (H3K14ac) when complexed with BRPF family proteins, while it mainly acetylates histone H4 lysine 5/8/12 when complexed with JADE family proteins (<xref ref-type="bibr" rid="bib20">Lalonde et al., 2013</xref>; <xref ref-type="bibr" rid="bib31">Mishima et al., 2011</xref>). HBO1 was recently identified as a therapeutic vulnerability of leukemia stem cells by genetic screening (<xref ref-type="bibr" rid="bib2">Au et al., 2020</xref>; <xref ref-type="bibr" rid="bib27">MacPherson et al., 2020</xref>). However, its molecular functions on leukemic proteins remain largely elusive. Our detailed structure/function analysis demonstrated that HBO1-MLL interaction promotes AEP-dependent gene activation in MLL fusion-mediated leukemic transformation. Moreover, another leukemic fusion of nucleoporin-98 (NUP98) and HBO1(i.e., NUP98-HBO1) also transformed HPCs via association with MLL. Hence, we propose that HBO1-MLL interaction modules can be utilized as molecular targets for developing drugs that specifically dismantle the oncogenic transcriptional machinery.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>THD2-mediated functions promote MLL fusion-dependent leukemic transformation</title><p>MLL fusion proteins confer unlimited self-renewal ability, leading to the immortalization of HPCs (<xref ref-type="bibr" rid="bib21">Lavau et al., 1997</xref>). MLL-ELL is among the frequently observed MLL fusions associated with acute myelogenous leukemia (<xref ref-type="bibr" rid="bib29">Meyer et al., 2018</xref>). To determine the domain structures required for MLL-ELL-mediated leukemic transformation, we performed myeloid progenitor transformation assays (<xref ref-type="bibr" rid="bib21">Lavau et al., 1997</xref>; <xref ref-type="bibr" rid="bib41">Okuda and Yokoyama, 2017b</xref>), wherein murine HPCs were retrovirally transduced with an MLL fusion gene and cultured in a semisolid medium supplemented with myeloid cytokines (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). MLL-ELL transformed HPCs, as previously reported (<xref ref-type="bibr" rid="bib7">DiMartino et al., 2000</xref>; <xref ref-type="bibr" rid="bib26">Luo et al., 2001</xref>), featured vigorous colony-forming capacities at the third and fourth passages, and showed elevated <italic>Hoxa9</italic> expression at the first and second passages. A deletion mutant lacking THD2 failed to transform (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), underscoring the biological significance of THD2. A minimalistic artificial construct of HA-tagged MTM fused to an intact Occludin homology domain (OHD) of ELL failed to transform HPCs (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, see MTMh-ELL″), whereas inclusion of THD2 to MTM (hereafter denoted as MTMT) caused constitutive activation of <italic>Hoxa9</italic> and immortalization of HPCs (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, see MTMTh-ELL″). These results indicate that MLL-ELL transforms HPCs through THD2-mediated functions.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Trithorax homology domain 2 (THD2)-mediated functions promote MLL-fusion-dependent leukemic transformation.</title><p>(<bold>A</bold>) Structure/function analysis of MLL-ELL. Various MLL-ELL constructs were examined for the transformation of myeloid progenitors. HA-tag (h: indicated as a red triangle) was fused to MTM and MTMT constructs. A schema of myeloid progenitor transformation assay is shown on top. <italic>Hoxa9</italic> expression normalized to <italic>Gapdh</italic> in first-round and second-round colonies (left) is shown as the relative value of MLL-ELL (arbitrarily set at 100%) with error bars (mean ± SD of PCR triplicates). Colony-forming ability at third- and fourth-round passages (right) is shown with error bars (mean ± SD of ≥3 biological replicates). IBD: integrase-binding domain; hMBM: high-affinity MENIN-binding motif; LBD: LEDGF-binding domain; THD1/2: trithorax homology domains 1 and 2; SET: Suver3-9/enhancer-of-zeste/trithorax motif; TED: transcription elongation domain; OHD: occludin homology domain. (<bold>B</bold>) Requirement of THD2 for various MLL fusion proteins in leukemic transformation. Various MLL fusion constructs were examined for the transformation of myeloid progenitors as in (<bold>A</bold>). RA1/2: RAS association domains 1/2; PDZ: PSD-95/Dlg/ZO-1 domain; OM: octapeptide motif; LZ: leucine zipper. MISD: minimum interaction site of DOT1L: YEATS: Yaf9 ENL AF9 Taf14 Sas5 domain; AHD: ANC1 homology domain. (<bold>C</bold>) Colony morphologies of MTMTh or MTMh-ENL′ transformed cells. The colonies on day 5 of fourth passage are shown with a scale bar. The ratio of compact colonies (≥100 total colonies were counted in each experiment) is shown on the left (mean ± SD of six biological replicates). Representative images are shown on the right.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Trithorax homology domain 2 (THD2) promotes MLL fusion-mediated leukemogenesis.</title><p>(<bold>A</bold>) Protein expression from various MLL fusion constructs. Virus-packaging cells transiently expressing each MLL fusion construct shown in <xref ref-type="fig" rid="fig1">Figure 1A and B</xref> and (<bold>B</bold>) were analyzed by western blotting with the indicated antibodies. The expected bands corresponding to the transgene products are indicated by a red arrow head. (<bold>B</bold>) Negative effects imposed by the loss of THD2 domain on transformation ex vivo. Various MLL fusion constructs lacking the THD2 domains were examined for the transformation of myeloid progenitors as in <xref ref-type="fig" rid="fig1">Figure 1A</xref>. (<bold>C</bold>) Negative effects imposed by the loss of THD2 domain on transformation in vivo. Leukemogenic activity of MLL fusion constructs was examined. Each MLL fusion construct was transduced to c-Kit-positive hematopoietic progenitors and transplanted into syngeneic mice (n=10). Statistical analysis was performed using the log-rank test and Bonferroni correction with the wild-type control. *p ≤ 0.05, ****p ≤ 0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Next, we tested the structural requirements of other MLL fusions (i.e., MLL-AF6, MLL-AF10, and MLL-ENL) (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). An MLL-AF6 fusion construct, in which MLL is fused to the RA1 and RA2 domains of AF6 (see MLL-AF6′), fully transformed HPCs as previously reported (<xref ref-type="bibr" rid="bib24">Liedtke et al., 2010</xref>). The minimalistic MTM-AF6 fusion construct (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, see MTMh-AF6′) activated <italic>Hoxa9</italic> expression in the early passages but produced modest numbers of colonies in later passages, while the inclusion of THD2 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, see MTMTh-AF6′) conferred much more vigorous transforming capacities. Deletion of THD2 from a PWWP-MLL-AF6 fusion construct containing the residues 641/1267 of MLL (P′641/1267h-AF6′) abrogated its transforming ability, suggesting that MLL-AF6 requires THD2 to exert its full transforming potential (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Nonetheless, an MLL-AF6′ construct lacking THD2 immortalized HPCs albeit less efficiently compared to MLL-AF6′ (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>, see MLL-AF6′ ΔTHD2), suggestive of some compensatory functions mediated by other MLL structures retained in MLL-AF6′ but missing in P′641/1267h-AF6′ (i.e., the residues 1/640 and 1268/1395). MLL-AF10 showed a similar trend, in line with our previous report (<xref ref-type="bibr" rid="bib39">Okuda et al., 2017</xref>; <xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A,B</xref>). In contrast, the oncogenic properties of MLL-ENL were not severely affected by the loss of THD2 in terms of colony-forming capacity (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>; <xref ref-type="bibr" rid="bib36">Okuda et al., 2014</xref>). However, the colony morphology of immortalized cells (ICs) transformed by the MTMh-ENL construct (MTMh-ENL′-ICs) was more differentiated compared to that of MTMTh-ENL′-ICs (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), suggesting that THD2 is required to block differentiation to some extent. Leukemogenesis in vivo was compromised by the deletion of THD2 for MLL-AF6, -AF10, and -ENL (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). These results indicate that MLL fusion proteins rely on THD2-mediated functions for leukemic transformation to varying degrees depending on their fusion partners. Among the MLL fusions tested, MLL-ELL most heavily relies on THD2-mediated functions.</p></sec><sec id="s2-2"><title>HBO1 complex associates with MLL proteins via THD2 at promoters</title><p>We previously showed that THD2 binds to AF4 family proteins (<xref ref-type="bibr" rid="bib39">Okuda et al., 2017</xref>). Indeed, a FLAG-tagged MLL construct encompassing the residues 869/1152 efficiently co-precipitated with exogenously expressed AF4 or AF5Q31 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>, see fMLL 869/1152+37aa). However, deletion of THD2 from the FLAG-tagged MLLΔFP construct (containing the residues 1/1395: fMLL ΔFP) did not impair co-precipitation of AF4, indicating that the interaction with AF4 is not mediated by THD2. Sequencing analysis of the vector constructs revealed that the fMLL 869/1152+37aa construct contained an additional coding sequence tethered in frame for 37 residues derived from the pCMV5 vector, which corresponds to a part of the chorionic somatomammotropin hormone 1 gene (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Removal of the additional 37 residues by introducing a stop codon resulted in complete loss of association with AF4 family proteins (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>, see fMLL 869/1251). Moreover, a FLAG-tagged GAL4 fusion construct tethered to the additional 37 residues co-precipitated with AF5Q31 (see fGAL4+37aa). Thus, we concluded that our previous claim for THD2 as a binding platform for AF4 family proteins was false.</p><p>To identify bona fide associating factors for THD2, we purified two exogenously expressed THD2-containing proteins (i.e., fGAL4-MLL 869/1124 and MTMTh) from the chromatin fraction of HEK293T cells using the fractionation-assisted chromatin immunoprecipitation (fanChIP) method (<xref ref-type="bibr" rid="bib33">Miyamoto and Yokoyama, 2021</xref>) and analyzed by mass spectrometry (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Components of the HBO1 complex including HBO1, PHF16 (also known as JADE3), MEAF6, and ING5 were detected in the purified materials (<xref ref-type="bibr" rid="bib3">Avvakumov et al., 2012</xref>). Immunoprecipitation-western blotting (IP-WB) analysis confirmed that fGAL4-MLL 869/1124 co-precipitated with HBO1 complex components but not with exogenously expressed AF4 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). A series of MTMT fusion proteins were associated with HBO1 and PHF16, while the respective MTM fusion proteins were not (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), confirming that THD2 mediates interaction with the HBO1 complex. Domain mapping analysis of MLL showed that the residues 869/1124 contain the major binding domains for the HBO1 complex (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). Moreover, fGAL4-MLL 1052/1124 co-precipitated with the HBO1 complex components after DNaseI treatment, indicating that association of MLL and HBO1 is not mediated by DNA (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>). It should be noted that a small amount of HBO1 co-precipitated with the MLL proteins lacking the THD2 domain (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>, see fMLL ΔFP ΔTHD2 and fMLL-ENL ΔTHD2), suggesting that there is a secondary binding domain for the HBO1 complex outside of THD2, which may account for the moderate effects of THD2 deletion from the full-length MLL fusion constructs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>HBO1 complex associates with MLL proteins at promoters.</title><p>(<bold>A</bold>) Purification of trithorax homology domain 2 (THD2) domain-associating factors. A FLAG-tagged (f: indicated as a blue triangle) GAL4 DNA-binding domain fused with the MLL fragment containing the residues 869–1124 or HA-tagged MTMT fragment was transiently expressed in HEK293T cells. A schema of the fractionation-assisted chromatin immunoprecipitation (fanChIP) method is shown on top. The transgene products were purified from the chromatin fraction and analyzed by mass spectrometry. Silver-stained images (right) of the purified materials are shown. Asterisk indicates the position of the transgene products. A Venn diagram of identified THD2 domain-associating factors by mass spectrometry is shown. (<bold>B</bold>) Association of GAL4-THD2 fusion with HBO1. Immunoprecipitation (IP)-western blotting of the chromatin fraction of HEK293T cells transiently expressing FLAG-tagged GAL4-MLL 869/1124 construct and Xpress-tagged AF4 (xAF4) was performed. Co-purification of HBO1, but not xAF4, was confirmed. #: the sample used for the input. (<bold>C</bold>) THD2-dependent association with the HBO1 complex. IP-western blotting of the chromatin fraction of virus-packaging cells, transiently expressing various HA-tagged MTMT (or MTM) fusion constructs, was performed. (<bold>D</bold>) Genomic localization of MLL and the HBO1 complex components in HB1119 cells. The ChIP followed by deep sequencing (ChIP-seq) profiles were visualized using the Integrative Genomics Viewer (The Broad Institute). The minimum value of the y-axis was set at 0, while the maximum value for each sample is indicated. (<bold>E</bold>) Average distribution of proteins near the transcription start sites (TSSs) of HB1119 cells. Genes whose MLL ChIP signal/input ratio at the promoter proximal transcribed region was ≥5 were defined as MLL target genes. Average ChIP signal distribution of indicated proteins at the MLL target genes (red) or all genes (black) is shown. The y-axis indicates the frequency of the ChIP-seq tag count (ppm) in 25 bp increments. (<bold>F</bold>) Requirement of HBO1 for myeloid progenitors immortalized by various oncogenes. sgRNA competition assays for <italic>Hbo1</italic> were performed on immortalized myeloid progenitors. The ratio of GFP-positive cells co-expressing sgRNA was measured by flow cytometry. sgRNA for Renilla luciferase (<italic>Ren</italic>) was used as a negative control, which does not affect proliferation. sgRNA for <italic>Rpa3</italic> was used as a positive control, which impairs proliferation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Trithorax homology domain 2 (THD2) does not mediate association with AF4 family proteins.</title><p>(<bold>A</bold>) AF4 family proteins bind the additional 37 residues derived from the expression vector. Immunoprecipitation-western blotting of the chromatin fraction of HEK293T cells transiently expressing various FLAG-tagged MLL constructs along with xAF4/xAF5Q31 was performed using fractionation-assisted chromatin immunoprecipitation (fanChIP) method. (<bold>B</bold>) Sequence of the additional residues derived from the pCMV5 vector. The coding sequences for the additional 37 amino acids were tethered to MLL in frame. A part of it corresponded to the chorionic somatomammotropin hormone 1 gene.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>HBO1 complex binds to MLL in various contexts.</title><p>(<bold>A</bold>) Domain mapping of MLL for interaction with the HBO1 complex. Immunoprecipitation (IP)-western blotting of the chromatin fraction of HEK293T cells transiently expressing various FLAG-tagged MLL constructs was performed as in <xref ref-type="fig" rid="fig2">Figure 2B</xref>. (<bold>B</bold>) Effects of DNase treatment on the interaction between MLL and the HBO complex. Co-precipitates were treated with DNaseI, washed multiple times, and analyzed by western blotting. DNA was detected by SYBR green. (<bold>C</bold>) Interaction with HBO1 through multiple contacts. IP-western blotting of the chromatin fraction of HEK293T cells transiently expressing various FLAG-tagged MLL constructs was performed as in <xref ref-type="fig" rid="fig2">Figure 2B</xref>. (<bold>D</bold>) Interaction between MLL proteins and HBO1 in HB1119 leukemia cells. IP-western blotting of the chromatin fraction of HB1119 cells was performed using an anti-MLL antibody. (<bold>E</bold>) Interaction between MLL and HBO1 in REH leukemia cells. IP-western blotting of the nucleosome fraction of REH leukemia cells was performed (using anti-MLL antibody) by the nucfrIP method.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>HBO1 is required for proliferation of MLL leukemia cells.</title><p>(<bold>A</bold>) Confirmation of chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) data by repeated ChIP-seq analyses. Duplicated ChIP-seq analyses in HB1119 cells were performed on each target proteins individually. (<bold>B</bold>) Requirement of HBO1 for various human leukemia cell lines. sgRNA competition assays for <italic>KAT7</italic> were performed on Cas9-expressing leukemia cell lines including HB1119, MV4-11, and REH. The ratio of GFP-positive cells co-expressing sgRNA was measured by flow cytometry. sgRNA for Renilla luciferase (<italic>Ren</italic>) was used as a negative control, which does not affect proliferation. sgRNA for <italic>RPA3</italic> was used as a positive control, which impairs proliferation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig2-figsupp3-v1.tif"/></fig></fig-group><p>Interaction between endogenous MLL proteins and HBO1 was confirmed in leukemia cell lines such as HB1119 and REH (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D,E</xref>). Chromatin immunoprecipitation (ChIP) followed by deep sequencing (ChIP-seq) of HB1119 cells, which endogenously express MLL-ENL, demonstrated that HBO1 complex components colocalized with MLL-ENL at the MLL target genes (e.g., <italic>MYC</italic>, <italic>HOXA9</italic>, and <italic>MYB</italic>) in a genome-wide manner (<xref ref-type="fig" rid="fig2">Figure 2D,E</xref> and <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>). CRISPR/Cas9-mediated sgRNA competition assays demonstrated that <italic>Kat7</italic>/<italic>KAT7</italic> (the gene encoding HBO1) is required for the proliferation of various MLL fusion-ICs (<xref ref-type="fig" rid="fig2">Figure 2F</xref>) and in human leukemia cell lines (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B</xref>). These results are consistent with the recent reports, which showed that the HBO1 complex associates with multiple MLL fusion proteins and plays a critical role in the maintenance of leukemia stem cells (<xref ref-type="bibr" rid="bib2">Au et al., 2020</xref>; <xref ref-type="bibr" rid="bib27">MacPherson et al., 2020</xref>). Taken together, MLL fusion proteins associate with the HBO1 complex through THD2 at the target promoters.</p></sec><sec id="s2-3"><title>MLL recruits the HBO1, AEP, and SL1 complexes to promoters</title><p>To elucidate the functional relationship between wild-type MLL and the HBO1 complex, we examined the genomic localization of the HBO1 complex, wild-type MLL, and its related transcriptional regulators in HEK293T cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). MLL localizes at the transcription start sites (TSSs) of CpG-rich genes including <italic>RPL13A</italic>, <italic>MYC</italic>, and <italic>CDKN2C</italic> (<xref ref-type="bibr" rid="bib39">Okuda et al., 2017</xref>). Distribution of the HBO1 complex was enriched at promoter proximal transcribed regions (0–2 kb from the TSS) (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) consistent with a previous report (<xref ref-type="bibr" rid="bib3">Avvakumov et al., 2012</xref>), suggesting its implication in transcription initiation/elongation. The HBO1 complex was localized at the MLL-occupied promoters in a genome-wide manner similarly to that in HB1119 cells. We previously showed that MLL associates with the MOZ complex and yet-to-be activated RNAP2 whose heptapeptide repeats are not phosphorylated (RNAP2 non-P) on target promoters, and that it colocalizes with various ENL-containing complexes including the AEP and DOT1L complexes (<xref ref-type="bibr" rid="bib32">Miyamoto et al., 2020</xref>; <xref ref-type="bibr" rid="bib39">Okuda et al., 2017</xref>). The ChIP signal intensities of MLL were highly correlated with those of HBO1, MOZ, and RNAP2 non-P (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), supporting the functional interactions of MLL with those MLL-associated factors. The ChIP signals of AEP (e.g., AF4, ENL) and SL1 (e.g., TAF1C) are weakly correlated with that of MLL, presumably because AEP and SL1 are indirectly recruited to MLL target promoters in a context-dependent manner.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>MLL recruits the HBO1 and AEP/SL1 complexes to promoters.</title><p>(<bold>A</bold>) Genomic localization of various transcriptional regulators/epigenetic marks in HEK293T cells. Chromatin immunoprecipitation (ChIP) followed by deep sequencing (ChIP-seq) analysis was performed on the chromatin of HEK293T cells for the indicated proteins/modifications. CIRA-seq data for unmethylated CpGs (unMe CpGs) and RNA-seq data are shown for comparison. (<bold>B</bold>) Average distribution of proteins near transcription start sites (TSSs) of HEK293T cells. Average ChIP signal distribution of indicated proteins at the MLL target genes (red) or all genes (black) is shown as in <xref ref-type="fig" rid="fig2">Figure 2E</xref>. (<bold>C</bold>) Relative occupation by multiple factors at all TSSs. ChIP-seq or CIRA-seq tags of indicated proteins at all genes were clustered into a 2 kb bin (0 to +2 kb from the TSS) and are presented as XY scatter plots. Spearman’s rank correlation coefficient (ρ) is shown. (<bold>D</bold>) Expression of MLL in MLL-deficient HEK293T cell lines. (<bold>E</bold>) Expression of MLL target genes in two independently generated MLL-deficient clones. Relative expression levels normalized to <italic>GAPDH</italic> are shown with error bars (mean ± SD of PCR triplicates) by RT-qPCR. Data are redundant with our previous report (<xref ref-type="bibr" rid="bib32">Miyamoto et al., 2020</xref>). (<bold>F</bold>) Localization of MLL, the HBO1 complex, the AEP complex, and the SL1 complex in two independently generated MLL-deficient clones. ChIP-qPCR was performed for indicated genes using qPCR probes designed for the TSS of each gene. ChIP signals are expressed as the percent input with error bars (mean ± SD of biological triplicates). Statistical analysis was performed by ordinary two-way ANOVA comparing each sample with the parent cells. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>MLL colocalizes with the HBO1 and AF4/ENL/P-TEFb (AEP)/SL1 complexes at promoters containing H3K4me3 marks.</title><p>(<bold>A</bold>) Confirmation of chromatin immunoprecipitation (ChIP) followed by deep sequencing (ChIP-seq) data by repeated ChIP-seq analyses. Duplicated ChIP-seq analyses in HEK293T cells were performed on each target proteins individually. (<bold>B</bold>) Localization of MLL, the HBO1 complex, the AEP complex, and the SL1 complex in two independently generated MLL-deficient clones. ChIP-qPCR was performed for indicated genes using qPCR probes designed for the transcription start site (TSS) of each gene. ChIP signals are expressed as the percent input with error bars (mean ± SD of PCR triplicates). Statistical analysis was performed by ordinary two-way ANOVA comparing each sample with the parent cells. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. (<bold>C</bold>) Localization of MLL mutants and HBO1 in MLL-deficient cells. ChIP-qPCR analysis on the MYC promoter was performed on the chromatin of MLL-deficient HEK293T cells (ΔMLL c3) transiently expressing HA-tagged MTM or MTMT constructs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig3-figsupp1-v1.tif"/></fig></fig-group><p>To examine the role of MLL in the genomic localization of the HBO1 complex, we analyzed MLL-deficient HEK293T cells by qRT-PCR and ChIP-qPCR. Depletion of MLL by the knockout of <italic>KMT2A</italic> (the gene encoding MLL) reduced the expression of <italic>MYC</italic> and <italic>CDKN2C</italic> (<xref ref-type="fig" rid="fig3">Figure 3D,E</xref>), as previously reported (<xref ref-type="bibr" rid="bib32">Miyamoto et al., 2020</xref>), and caused a marked reduction in the ChIP signals of the HBO1 complex components (i.e., PHF16, MEAF6) at the <italic>MYC</italic> and <italic>CDKN2C</italic> loci (<xref ref-type="fig" rid="fig3">Figure 3F</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). The HBO1 complex is presumed to target the chromatin containing histone H3 lysine 4 (H3K4me3) marks to which the PHD finger of the ING5 subunit specifically binds (<xref ref-type="bibr" rid="bib6">Champagne et al., 2008</xref>). H3K4me3 marks were substantially reduced at the <italic>MYC</italic> and <italic>CDKN2C</italic> promoters as they were presumably provided by MLL in part. These results suggest that the decreased presence of the HBO1 complex may be due to the reduced H3K4me3 marks. Transient expression of a THD2-containing MLL construct (MTMTh) did not rescue the recruitment of the HBO1 complex onto the MYC promoter (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>), suggesting that H3K4 methylation is a prerequisite for the recruitment of the HBO1 complex. In addition, the ChIP signals of AEP/SL1 components (i.e., ENL, CCNT1, AF4, and TAF1C) were also reduced at these loci (<xref ref-type="fig" rid="fig3">Figure 3F</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). These results indicate that MLL recruits the HBO1, AEP, and SL1 complexes to the MYC and CDKN2C promoters in part via H3K4 methylation.</p></sec><sec id="s2-4"><title>MLL-ELL transforms through the common binding platform for AF4 and EAF1</title><p>Because MLL-ELL is highly dependent on THD2-mediated HBO interaction, we next dissected the function of the ELL portion in MLL-ELL-mediated leukemic transformation. ELL has a transcriptional elongation activity and is associated with a variety of proteins including AF4 and EAF family proteins (<xref ref-type="bibr" rid="bib25">Lin et al., 2010</xref>; <xref ref-type="bibr" rid="bib45">Shilatifard et al., 1996</xref>; <xref ref-type="bibr" rid="bib48">Simone et al., 2003</xref>; <xref ref-type="bibr" rid="bib47">Simone et al., 2001</xref>). Myeloid progenitor transformation assays demonstrated that an intact OHD, which is responsible for the association with both AF4 and EAF1 (<xref ref-type="bibr" rid="bib25">Lin et al., 2010</xref>; <xref ref-type="bibr" rid="bib47">Simone et al., 2001</xref>), is required for transformation as previously reported (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>; <xref ref-type="bibr" rid="bib7">DiMartino et al., 2000</xref>; <xref ref-type="bibr" rid="bib26">Luo et al., 2001</xref>). ChIP-qPCR analysis of FLAG-tagged GAL4 constructs fused to ELL confirmed that OHD is responsible for the recruitment of both AF4 and EAF1 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). Deletion of OHD resulted in the loss of interaction with both AF4 and EAF1 family proteins, which is correlated with the transforming properties (<xref ref-type="fig" rid="fig4">Figure 4B</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). It should be noted that several processed forms of AF4 (e.g., 110 kDa) were observed in the co-precipitates, whose amounts were specifically increased in the chromatin fraction of HEK293T cells transiently expressing GAL4-ELL proteins harboring an intact OHD (<xref ref-type="fig" rid="fig4">Figure 4B</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>), suggesting that ELL induces the processing of AF4 and tethers both processed and unprocessed forms of AF4 to the chromatin. ELL-AF4 interaction was attenuated by co-expression of EAF1, whereas ELL-EAF1 interaction was augmented by co-expression of AF4 (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref>), suggesting that these interactions occur sequentially but not simultaneously, wherein the ELL-AF4 interaction precedes the ELL-EAF1 interaction (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Taken together, MLL-ELL exerts its transforming properties through the common binding platform for AF4 and EAF1.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>MLL-ELL transforms through the common binding platform for AF4 and EAF1.</title><p>(<bold>A</bold>) Requirement of the occludin homology domain (OHD) in MLL-ELL-mediated transformation. Various MLL-ELL constructs carrying mutations in the ELL portion were examined for the transformation of myeloid progenitors, as in <xref ref-type="fig" rid="fig1">Figure 1A</xref>. NHD: N-terminal homology domain; ALF: AF4/LAF4/FMR2 homology domain; pSER: poly-serine; A9ID: AF9 interaction domain; CHD: C-terminal homology domain; EHD: EAF family homology domain; DLXLS: DLXLS motif; SDE: SDE motif. (<bold>B</bold>) OHD-dependent association with AF4. Immunoprecipitation (IP)-western blotting of the chromatin fraction of virus-packaging cells, transiently expressing various HA-tagged MTMT-ELL fusion constructs, was performed. Endogenous AF4 proteins co-purified with MTMTh-ELL proteins were visualized by an anti-AF4 antibody. (<bold>C</bold>) Sequential recruitment of AF4 and EAF1 by ELL. HEK293TL cells (<xref ref-type="bibr" rid="bib37">Okuda et al., 2015</xref>), which harbor GAL4-responsive reporter, were transfected with various combinations of FLAG-tagged GAL4 fusion proteins, xAF4, and HA-tagged EAF1 (EAF1h), and were subjected to chromatin immunoprecipitation (ChIP)-qPCR analysis. A qPCR probe near the GAL4-responsive elements (UAS) was used. The ChIP signals were expressed as the percent input with error bars (mean ± SD of PCR triplicates). TATA: TATA box; LUC: luciferase. (<bold>D</bold>) Effects of overexpression of AF4 or EAF1 on ELL complex formation. IP-western blotting of the chromatin fraction of HEK293TL cells, transiently expressing various combinations of FLAG-tagged GAL4-ELL proteins, xAF4, and EAF1h, was performed. (<bold>E</bold>) A model of the sequential association between ELL, AF4 family proteins, and EAF family proteins.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Functions of the ELL portion.</title><p>(<bold>A</bold>) Virus-packaging cells transiently expressing each MLL fusion construct were analyzed by western blotting with indicated antibodies. (<bold>B</bold>) Recruitment of exogenously expressed AF4 or EAF1 by ELL. HEK293TL cells (<xref ref-type="bibr" rid="bib37">Okuda et al., 2015</xref>), which harbor GAL4-responsive reporter, were transfected with FLAG-tagged GAL4 fusion proteins, xAF4, and HA-tagged EAF1 (EAF1h), and were subjected to chromatin immunoprecipitation (ChIP)-qPCR analysis. A qPCR probe near the GAL4-responsive elements (UAS) was used. The ChIP signals were expressed as the percent input with error bars (mean ± SD of PCR triplicates). TATA: TATA box; LUC: luciferase. (<bold>C</bold>) Association of ELL with exogenously expressed AF4 or EAF1 on chromatin. Immunoprecipitation (IP)-western blotting of the chromatin fraction of HEK293TL cells transiently expressing various FLAG-tagged GAL4-ELL proteins along with xAF4 and EAF1h was performed.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>AF4 and EAF1 form two distinct SL1/MED26-containing complexes</title><p>AF4 and EAF1 family proteins share some structural similarities; both have the SDE motif enriched with serine, aspartic acid, and glutamic acid, and the DLXLS motif whose consensus sequence is LXXDLXLS (<xref ref-type="fig" rid="fig5">Figure 5A,B</xref>). The NKW motif was found in the AF4 family but not in the EAF family. The SDE motif of AF4 associates with the SL1 complex and its DLXLS motif associates with MED26 (<xref ref-type="bibr" rid="bib37">Okuda et al., 2015</xref>; <xref ref-type="bibr" rid="bib38">Okuda et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Takahashi et al., 2011</xref>). IP-WB analysis demonstrated that EAF1 was also associated with SL1 and MED26 through its C-terminal domain containing the SDE and DLXLS motifs (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, see fGAL4-EAF1-C). ChIP-qPCR analysis confirmed that the C-terminal portion of EAF1 recruited TAF1C and MED26 to the GAL4-responsive promoter (<xref ref-type="fig" rid="fig5">Figure 5D</xref>, see fGAL4-EAF1-C). Nevertheless, the GAL4-ELL fusion failed to associate with or recruit TAF1C and MED26 (<xref ref-type="fig" rid="fig5">Figure 5C,D</xref>, see fGAL4-ELL′), indicating that ELL-bound EAF1 or AF4 is unable to interact with TAF1C and MED26, and therefore must dissociate from ELL to form a complex with SL1 and MED26 (<xref ref-type="fig" rid="fig5">Figure 5E,F</xref>). It should be noted that GAL4-EAF1 failed to pull down endogenous AF4 and ENL (<xref ref-type="fig" rid="fig5">Figure 5C,D</xref>, see fGAL4-EAF1), while a GAL4-AF4 protein containing an ELL-binding domain (ALF) also failed to pull down exogenously expressed EAF1 (<xref ref-type="fig" rid="fig5">Figure 5C,D</xref>, see fGAL4-AF4-2N and C), indicating that the AF4/ELL/EAF1 trimer complex is unstable and that ELL mostly binds AF4 or EAF family proteins in a mutually exclusive manner.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>AF4 and EAF1 form distinct SL1/MED26-containing complexes.</title><p>(<bold>A</bold>) A schema of the structures of AF4, ELL, and EAF1. ALF is responsible for interaction with ELL, pSER is responsible for interaction with SL1, and DLXLS is responsible for interaction with MED26. EAF family homology domain (EHD) is responsible for homodimerization and interaction with ELL. NKW:NKW motif responsible for transcriptional activation. (<bold>B</bold>) Alignment of the amino acid sequences of the SDE, DLXLS, and NKW motifs of human AF4 family proteins and EAF family proteins. Conserved residues are indicated by asterisks. (<bold>C</bold>) Association of EAF1, ELL, and AF4 domains with various associating factors on chromatin. Immunoprecipitation (IP)-western blotting of the chromatin fraction of HEK293TL cells transiently expressing various FLAG-tagged GAL4 fusion proteins, with or without indicated HA-tagged constructs, was performed as in <xref ref-type="fig" rid="fig4">Figure 4D</xref>. Endogenous proteins were detected by specific antibodies for each protein, while exogenous proteins were detected by antibodies for FLAG or HA tag. (<bold>D</bold>) Recruitment of various transcriptional regulatory proteins by EAF1, ELL, and AF4 domains. Chromatin immunoprecipitation (ChIP)-qPCR analysis of HEK293TL cells transiently expressing various combinations of FLAG-tagged GAL4 fusion proteins along with indicated HA-tagged constructs was performed as in <xref ref-type="fig" rid="fig4">Figure 4C</xref>. (<bold>E</bold>) Putative complex recruitment mediated by ELL-AF4 interaction. (<bold>F</bold>) Putative complex recruitment mediated by ELL-EAF1 interaction. (<bold>G</bold>) Structural requirement of MTM-AF4 pSER fusion and MTMT-EAF1 fusion. Various MTMh/MTMTh constructs fused with EAF1 domains were examined for the transformation of myeloid progenitors as in <xref ref-type="fig" rid="fig1">Figure 1A</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Roles for AF4/ENL/P-TEFb (AEP) in MLL-ELL-mediated leukemic transformation, related to <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title><p>(<bold>A</bold>) Protein expression from various MLL fusion constructs. Virus-packaging cells transiently expressing each MLL fusion construct were analyzed by western blotting with indicated antibodies. (<bold>B</bold>) Effects of <italic>Mllt1</italic> knockdown on MLL-ELL- and MLL-ENL-ICs. MLL-ELL- and MLL-ENL-ICs were transduced with shRNA for endogenous <italic>Mllt1</italic> and analyzed for gene expression normalized to <italic>Gapdh</italic> by qRT-PCR (mean ± SD of PCR triplicates) and relative colony-forming units (mean ± SD of ≥3 biological replicates).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig5-figsupp1-v1.tif"/></fig></fig-group><p>In addition, GAL4-EAF1 co-precipitated with exogenously expressed EAF1 through the EAF family homology domain (EHD), indicating that EAF1 forms a homodimer (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, see the HA blot of exogenously expressed HA-tagged EAF1). It has been shown that EAF1 binds to ELL through two distinct contacts (<xref ref-type="bibr" rid="bib48">Simone et al., 2003</xref>). Accordingly, both N- and C-terminal halves of EAF1 co-precipitated with endogenous ELL (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, see fGAL4-EAF1-N and -C in the upper ELL blot). However, when EAF1 was overexpressed, co-precipitation of endogenous ELL by the C-terminal half of EAF1 was no longer detected (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, see fGAL4-EAF1-C in the lower ELL blot), suggesting that free ELL preferentially binds to the EAF1 dimer over the monomeric C-terminal half of EAF1. GAL4-ELL co-precipitated with endogenous ELL presumably mediated by an EAF1 dimer (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, see fGAL4-ELL′ in the upper ELL blot), whereas it failed to pull down ELL when exogenous ELL was overexpressed to absorb free EAF1 dimers (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, see fGAL4-ELL′ in the HA blot of exogenously expressed HA-tagged ELL). Taken together, these results suggest that ELL forms at least two different stable complexes, one is with AF4 family proteins, which subsequently leads to the formation of an AEP/SL1/MED26 complex (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), and the other is an EAF1/ELL homodimer complex, which leads to the formation of an EAF1/SL1/MED26 complex (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). These two SL1/MED26 containing complexes are similar in composition but different in three key functions. The AEP/SL1/MED26 complex has the NKW motif which is required for AF4-dependent gene activation (<xref ref-type="bibr" rid="bib37">Okuda et al., 2015</xref>), and contains P-TEFb which promotes transcription elongation, and ENL family proteins which tether AEP on acetylated chromatin (<xref ref-type="bibr" rid="bib9">Erb et al., 2017</xref>; <xref ref-type="bibr" rid="bib22">Li et al., 2014</xref>; <xref ref-type="bibr" rid="bib56">Wan et al., 2017</xref>). Thus, we presumed that the AEP/SL1/MED26 complex is competent for transactivation whereas the EAF1/SL1/MED26 complex is not.</p></sec><sec id="s2-6"><title>MLL-ELL-mediated leukemic transformation is driven by interaction with AEP, while MLL-EAF1-mediated transformation is promoted by homodimerization</title><p>Previously, <xref ref-type="bibr" rid="bib26">Luo et al., 2001</xref>, demonstrated that an artificial fusion construct of MLL and EAF1 transformed HPCs and induced leukemia, which suggested that the ELL-EAF1 interaction, rather than ELL-AEP interaction, played a major role in MLL-ELL-mediated leukemic transformation. To examine the structural requirements for MLL-EAF1-mediated transformation, we generated artificial fusion constructs in which MTM or MTMT is fused to EAF1 domains and examined their transforming properties (<xref ref-type="fig" rid="fig5">Figure 5G</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). As reported previously (<xref ref-type="bibr" rid="bib37">Okuda et al., 2015</xref>), an MTM construct fused to an AF4 portion containing the SDE and NKW motifs (i.e., MTMh-AF4-2C-abc) activated <italic>Hoxa9</italic> expression and immortalized HPCs, while a similar construct lacking the NKW motif (i.e., MTMh-AF4-2C-ab) failed to transform (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Accordingly, an MTM construct fused to the C-terminal half of EAF1 containing the SDE motif but lacking the NKW motif failed to transform HPCs (<xref ref-type="fig" rid="fig5">Figure 5G</xref>, see MTMh-EAF1-C). However, an MTM construct fused to the entire EAF1 demonstrated partial transforming properties, which maintained the expression of <italic>Hoxa9</italic> in the early passages, but failed to immortalize HPCs (<xref ref-type="fig" rid="fig5">Figure 5G</xref>, see MTMh-EAF1). MTMT constructs fused to the EHD fully transformed HPCs (<xref ref-type="fig" rid="fig5">Figure 5G</xref>, see MTMTh-EAF1 and MTMTh-EAF1-N). This trend is reminiscent of MLL-AF6 which transforms HPCs by homodimerization (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="bibr" rid="bib24">Liedtke et al., 2010</xref>) and suggests that MLL-EAF1 transforms by EHD-mediated homodimerization rather than by ELL-EAF1 interaction. Knockdown of <italic>Mllt1</italic> (the gene encoding ENL) in MLL-ELL-ICs perturbed colony formation and <italic>Hoxa9</italic> expression, while its effects on MLL-ENL-ICs were relatively limited presumably because MLL-ENL can directly recruit AEP (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). With these results, we speculated that MLL-ELL transforms HPCs through the recruitment of AEP, while MLL-EAF1 transforms via homodimerization in a mechanism similar to MLL-AF6.</p></sec><sec id="s2-7"><title>MLL-ELL transforms HPCs via association with AEP, but not with EAF1 or p53</title><p>To further evaluate the significance of ELL-AF4 and ELL-EAF1 interactions in MLL-ELL-mediated leukemic transformation, we introduced S600A/K606T double mutation (hereafter denoted as SA/KT) to the ELL portion, which was initially predicted to impair ELL-AF4 interaction based on the structural data for the ELL2/AF5Q31 complex (<xref ref-type="bibr" rid="bib43">Qi et al., 2017</xref>). Indeed, the mutation severely attenuated ELL-AF4 interaction (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, see fGAL4-ELL″ SA/KT). However, a substantial amount of AF4 (mostly the processed forms of AF4) remained associated with the SA/KT mutant, while co-precipitation of EAF1 was completely abolished. These results suggest that SA/KT mutation abolishes the primary contact of ELL for AF4 and EAF1, while there is an additional contact for AF4 that is unaffected by this mutation. Western blotting of the input samples of the chromatin fraction showed that the SA/KT mutant increased the amount of processed forms of AF4 in the chromatin fraction like the intact form (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, see fGAL4-ELL″ and fGAL4-ELL″SA/KT in the Xpress blot), thus further confirming the interaction with fGAL4-ELL″ SA/KT and AF4. ChIP-qPCR analysis confirmed that exogenously expressed AF4 was recruited to the target chromatin by fGAL4-ELL″ SA/KT, while EAF1 was not (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Moreover, fGAL4-ELL″ SA/KT co-precipitated endogenous AF4 and AF5Q31 (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>), while it failed to pull down p53, another ELL associating factor (<xref ref-type="bibr" rid="bib59">Wiederschain et al., 2003</xref>). fGAL4-ELL″ SA/KT recruited a substantial amount of endogenous ENL and CyclinT1 to the GAL4-responsive promoter (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>), indicating that the SA/KT mutant is competent for loading AEP onto chromatin.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>MLL-ELL transforms hematopoietic progenitors via association with AF4/ENL/P-TEFb (AEP), but not with EAF1 or p53.</title><p>(<bold>A</bold>) Mutations of ELL selectively abrogate interaction with EAF1. Immunoprecipitation (IP)-western blotting of the chromatin fraction of HEK293TL cells transiently expressing FLAG-tagged GAL4-ELL proteins with or without S600A/K606T substitutions (SA/KT) along with xAF4 and EAF1h was performed as in <xref ref-type="fig" rid="fig4">Figure 4D</xref>. (<bold>B</bold>) Recruitment of exogenously expressed AF4 or EAF1 by ELL mutant proteins. Chromatin immunoprecipitation (ChIP)-qPCR analysis of HEK293TL cells transiently expressing FLAG-tagged GAL4-ELL proteins with or without the SA/KT mutation along with xAF4 and EAF1h was performed as in <xref ref-type="fig" rid="fig4">Figure 4C</xref>. (<bold>C</bold>) Effects of the SA/KT mutation on MLL-ELL-mediated leukemic transformation ex vivo. Various MLL-ELL constructs with or without the SA/KT mutation were examined for the transformation of myeloid progenitors as in <xref ref-type="fig" rid="fig1">Figure 1A</xref>. (<bold>D</bold>) Effects of the SA/KT mutation on MLL-ELL-mediated leukemic transformation in vivo. MLL-ELL or its SA/KT mutant was transduced to c-Kit-positive hematopoietic progenitors and transplanted into syngeneic mice (n = 20). Primary leukemia cells were harvested from the bone marrow and transplanted into secondary recipient mice (n = 20). (<bold>E</bold>) Enhanced interaction of ELL with AEP mediated by the trithorax homology domain 2 (THD2) domain. IP-western blotting of the chromatin fraction of virus-packaging cells, transiently expressing various HA-tagged MTMT-ELL fusion constructs (with or without the SA/KT mutation), was performed. Endogenous proteins co-purified with MLL-ELL proteins were visualized by specific antibodies.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Roles for EAF1 and p53 in MLL-ELL-mediated transformation 6.</title><p>(<bold>A</bold>) Mutations in ELL selectively abrogated the interaction with p53. Immunoprecipitation (IP)-western blotting of the chromatin fraction of HEK293TL cells transiently expressing FLAG-tagged GAL4-ELL proteins with or without S600A/K606T substitutions (SA/KT) was performed as in <xref ref-type="fig" rid="fig4">Figure 4D</xref>. Endogenous AF4 family proteins and p53 co-purified with GAL4-ELL proteins were detected by anti-AF4-, AF5Q31-, and p53-antibodies. (<bold>B</bold>) Recruitment of endogenous AF4/ENL/P-TEFb complex (AEP) proteins by ELL mutant proteins. Chromatin immunoprecipitation (ChIP)-qPCR analysis of HEK293TL cells transiently expressing FLAG-tagged GAL4-ELL proteins with or without the SA/KT mutation was performed as in <xref ref-type="fig" rid="fig4">Figure 4C</xref>. ChIP signals of endogenous ENL and CyclinT1 were detected using the anti-ENL and CyclinT1 antibodies. (<bold>C</bold>) Protein expression from various MLL fusion constructs. Virus-packaging cells, transiently expressing each MLL fusion construct, were analyzed by western blotting with the indicated antibodies. (<bold>D</bold>) Requirement of EAF1 and p53 for MLL-ELL-immortalized cells. sgRNA competition assays for <italic>Eaf1</italic> and <italic>Trp53</italic> were performed as in <xref ref-type="fig" rid="fig2">Figure 2F</xref>. (<bold>E</bold>) Sensitivity to pan MYST HAT inhibitor. Leukemia cells (LCs) for various MLL fusions were cultured in the presence of WM1119, a pan MYST HAT inhibitor, and their relative colony-forming units (mean ± SD of thee biological replicates) were monitored.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig6-figsupp1-v1.tif"/></fig></fig-group><p>Next, we examined the effects of the SA/KT mutation on the transforming properties of MLL-ELL. Both <italic>Hoxa9</italic> expression and colony-forming potentials were maintained by MLL-ELL SA/KT-ICs (<xref ref-type="fig" rid="fig6">Figure 6C</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>). Remarkably, the MTM construct fused to ELL carrying the SA/KT mutation activated <italic>Hoxa9</italic> and immortalized HPCs albeit with low clonogenicity despite the lack of THD2 (<xref ref-type="fig" rid="fig6">Figure 6C</xref>, see MTMh-ELL″ SA/KT), suggesting that the SA/KT mutation partially compensates for the lack of interaction with the HBO1 complex. MLL-ELL SA/KT induced leukemia in vivo (<xref ref-type="fig" rid="fig6">Figure 6D</xref>), indicating that direct recruitment of EAF1 or p53 is dispensable and potentially suppressive for MLL-ELL-mediated leukemic transformation. sgRNA competition assays showed that loss of <italic>Eaf1</italic> has a marginal inhibitory effect on proliferation of MLL-ELL-ICs ex vivo, while loss of <italic>Trp53</italic> accelerated it, suggestive of non-essential roles for EAF1 and an inhibitory role for p53 in MLL-ELL-mediated transformation (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>). IP-WB analysis of the MTMh- or MTMTh-ELL″ SA/KT showed that association with AF4 and ENL through the presumed secondary contact is enhanced by the presence of THD2 while p53 association remained abolished (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Leukemia cells of MLL-ELL were particularly sensitive to WM1119, a pan MYST family HAT inhibitor (<xref ref-type="bibr" rid="bib27">MacPherson et al., 2020</xref>), compared to other MLL fusion-leukemia cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>), suggesting that HBO1-mediated protein acetylation may enhance the ELL-AF4 association. In summary, these results suggested that MLL-ELL transforms HPCs via interaction with AF4 family proteins, which is promoted by the HBO1 complex but hindered by other ELL-associated factors.</p></sec><sec id="s2-8"><title>NUP98-HBO1 fusion transforms myeloid progenitors through interaction with MLL</title><p>NUP98-HBO1 fusion has been found in chronic myelomonocytic leukemia and was shown to induce clinically relevant leukemia in mice (<xref ref-type="bibr" rid="bib13">Hayashi et al., 2019</xref>). NUP98-HBO1 transformed HPCs ex vivo, which was accompanied by high <italic>Hoxa9</italic> expression (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Fusion of NUP98 and homeodomain proteins (e.g., NUP98-HOXA9) has been shown to induce leukemia in mouse models (<xref ref-type="bibr" rid="bib19">Kroon et al., 2001</xref>). The homeodomain of HOXA9 possesses a sequence-specific DNA-binding ability. ChIP-qPCR analysis demonstrated that FLAG-tagged NUP98-HOXA9 (fNUP98-HOXA9) bound to the HOXA9-binding site within the HOXA7 locus, whereas fNUP98-HBO1 did not (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>), suggesting that HBO1 provides an alternative chromatin targeting function that differs from that of the HOXA9 homeodomain. Because the HBO1 complex binds MLL (<xref ref-type="fig" rid="fig7">Figure 7B</xref>), we hypothesized that the HBO1 portion might confer a targeting ability through association with MLL. To test this hypothesis, we generated an artificial NUP98 fusion construct in which MENIN is fused to NUP98 and examined its transforming properties. Indeed, NUP98-MENIN transformed HPCs (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Artificial NUP98 constructs fused with an HBO complex component (i.e., fNUP98-MEAF6 or -ING5) also transformed HPCs. IP-western blotting showed that these artificial NUP98 fusions were associated with MLL in the chromatin fraction, supporting the hypothesis that NUP98-HBO1 transforms HPCs via interaction with MLL (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). The NUP98 portion did not co-precipitate MLL in this setting (<xref ref-type="fig" rid="fig7">Figure 7D</xref>, see fNUP98ΔFP), consistent with a previous report (<xref ref-type="bibr" rid="bib46">Shima et al., 2017</xref>). However, it should be noted that the NUP98 portion was shown to localize in proximity with MLL (<xref ref-type="bibr" rid="bib60">Xu et al., 2016</xref>) and promote the physical interaction of NUP98-HOXA9 with MLL (<xref ref-type="bibr" rid="bib46">Shima et al., 2017</xref>). The sgRNA competition assay demonstrated fNUP98-HBO1-ICs depended on MLL for continuous proliferation (<xref ref-type="fig" rid="fig7">Figure 7E</xref>), similarly to fNUP98-HOXA9-ICs as reported previously (<xref ref-type="bibr" rid="bib46">Shima et al., 2017</xref>; <xref ref-type="bibr" rid="bib60">Xu et al., 2016</xref>). However, both fNUP98-HOXA9- and fNUP98-HBO1-ICs were mildly sensitive to MENIN-MLL interaction inhibitor (MI-2–2) (<xref ref-type="bibr" rid="bib44">Shi et al., 2012</xref>), and were not rendered completely differentiated unlike MLL-AF10-ICs at the concentration of 10 μM (<xref ref-type="fig" rid="fig7">Figure 7F</xref>), suggesting that a MENIN-less MLL complex may sufficiently recruit NUP98-HBO1 to the target chromatin. Interestingly, E508Q amino acid substitution, which kills its HAT activity (<xref ref-type="bibr" rid="bib10">Foy et al., 2008</xref>) but retains the binding capacities to MLL (<xref ref-type="fig" rid="fig7">Figure 7D</xref>), did not impair the transforming property of NUP98-HBO1 (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Moreover, WM1119 did not induce complete differentiation of NUP98-HBO1-ICs, as seen in MLL-AF10-ICs, at 10 μM (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>). These results indicate that the interaction with MLL, and not the intrinsic HAT activity, mediates NUP98-HBO1-mediated leukemic transformation.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Nucleoporin-98 (NUP98)-HBO1 fusion transforms myeloid progenitors through interaction with MLL.</title><p>(<bold>A</bold>) Structural requirement of NUP98-HBO1 fusion. Various NUP98 fusion constructs were examined for the transformation of myeloid progenitors (along with an HBO1 construct) as in <xref ref-type="fig" rid="fig1">Figure 1A</xref>. Relative <italic>Hoxa9</italic> expression in first round colonies was analyzed. Asterisk indicates that the qPCR probe detected a human HOXA9 coding sequence included in the NUP98-HOXA9 construct in addition to endogenous murine <italic>Hoxa9</italic>. Zn: zinc finger; MYST: MYST HAT domain; HD: homeodomain; FG: phenylalanine-glycine repeat. (<bold>B</bold>) Association with MLL by NUP98-HBO1. The chromatin fraction of virus-packaging cells transiently expressing the indicated transgenes was subjected to immunoprecipitation (IP)-western blotting. Endogenous MLL<sup>C</sup> fragment was detected by a specific anti-MLL antibody. (<bold>C</bold>) Structural requirement of various NUP98 fusions for leukemic transformation. Indicated NUP98 fusion constructs were examined for the transformation of myeloid progenitors as in <xref ref-type="fig" rid="fig1">Figure 1A</xref>. ING: inhibitor of growth domain of ING4 and ING5; NuA4: histone acetyltransferase subunit NuA4; EPcA-I/II: enhancer of polycomb A domains I and II. (<bold>D</bold>) Association with MLL by various NUP98 fusions. IP-western blotting was performed as in (<bold>B</bold>). (<bold>E</bold>) Requirement of MLL for NUP98 fusion-immortalized cells. sgRNA competition assays for <italic>Kmt2a</italic> were performed on NUP98-HOXA9- and NUP98-HBO1-immortalized cells as in <xref ref-type="fig" rid="fig2">Figure 2F</xref>. (<bold>F</bold>) Effects of pharmacologic inhibition of MENIN-MLL interaction on NUP98 fusion-immortalized cells. NUP98-HBO1- and NUP98-HOXA9-immortalized cells were cultured in the presence of 10 μM of MI-2–2 MENIN-MLL interaction inhibitor, and their proliferation was monitored every 3 days. MLL-AF10-immortalized cells were also analyzed as a positive control. VC: vehicle control.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Functional differences between nucleoporin-98 (NUP98)-HOXA9 and NUP98-HBO1.</title><p>(<bold>A</bold>) Targeting ability to the HOXA9-binding site. Virus-packaging cells transiently expressing indicated transgenes were subjected to chromatin immunoprecipitation (ChIP)-qPCR analysis. The percent input values of each probe (mean ± SD of PCR triplicates) are shown. A HOXA9-binding site was previously identified at the HOXA7 locus (<xref ref-type="bibr" rid="bib46">Shima et al., 2017</xref>). The CD4 locus was analyzed as a negative control. (<bold>B</bold>) Effects of pharmacologic inhibition of MYST HATs on NUP98 fusion-immortalized cells. NUP98-HBO1- and NUP98-HOXA9-ICs were cultured in the presence of 10 μM of WM1119 MYST HAT inhibitor and their proliferation was monitored every 3 days. MLL-AF10-immortalized cells were also analyzed as the positive control. VC: vehicle control.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig7-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-9"><title>Association of MLL with the HBO1 complex is mainly mediated by PHF16 and ING4/5</title><p>To dissect the mechanism of association between MLL and the HBO1 complex, we performed IP-WB analyses of the chromatin fractions from HEK293T cells transiently expressing the MLL bait protein (fMLL 869–1124) in combination with each component of the HBO1 complex. Only PHF16 and ING5 were weakly detected in the co-precipitates of the MLL bait protein; however, a very strong association was observed when all of the HBO1 complex components were co-expressed (<xref ref-type="fig" rid="fig8">Figure 8A</xref>), suggesting that the association of MLL with the HBO1 complex is mediated via multiple contacts likely provided by PHF16 and ING5. IP-WB analysis wherein each component of the HBO1 complex was omitted indicated the PHF16 and ING5 are indeed the most influential components for the MLL-HBO1 complex association (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). Notably, the omission of HBO1 reduced the association albeit to a much lesser extent, which can be rescued by adding back the C-terminal half of HBO1 that mediates interaction with PHF16 and ING5. The omission of MEAF6 also reduced the association substantially, indicating that the formation of the entire HBO1 complex maximizes the potential of the MLL-HBO1 complex association. Deletion of the ING domain from ING5 resulted in the loss of the MLL-HBO1 complex association, suggesting that the ING domain may provide a direct contact for MLL interaction. Point mutations of the aromatic cage of the PHD finger of ING5 (Y188A and W211A) that directly binds to H3K4me3 marks (<xref ref-type="bibr" rid="bib6">Champagne et al., 2008</xref>) resulted in the loss of the MLL-HBO1 complex association, which could be rescued by ING4 (<xref ref-type="fig" rid="fig8">Figure 8C</xref>), indicating that ING4/5-mediated chromatin binding to H3K4me3 marks is required for efficient MLL-HBO1 complex association. These results suggest that ING4/5-mediated chromatin binding precedes the MLL-HBO1 complex association, and the MLL and HBO1 complexes stably associate with each other on the chromatin containing H3K4me3 marks to promote subsequent AEP/SL1-mediated transcriptional activation by MLL fusions (<xref ref-type="fig" rid="fig8">Figure 8D</xref>).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>MLL-HBO1 complex association is mediated by multiple contacts and in a chromatin-bound context containing H3K4 methylation.</title><p>(<bold>A</bold>) Association of the MLL bait protein with the HBO1 complex. Immunoprecipitation (IP)-western blotting of the chromatin fraction of HEK293T cells transiently expressing FLAG-tagged MLL 869/1124 construct and Xpress-tagged HBO1 complex components was performed. (<bold>B</bold>) Influence of each HBO1 complex component for MLL-HBO1 complex association. (<bold>C</bold>) Domain mapping of ING5 responsible for MLL-HBO1 complex association. (<bold>D</bold>) Models of MLL-ELL- and nucleoporin-98 (NUP98)-HBO1-mediated gene activation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65872-fig8-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Most MLL fusion proteins constitutively recruit AEP by a variety of mechanisms to immortalize HPCs (<xref ref-type="bibr" rid="bib51">Takahashi and Yokoyama, 2020</xref>). However, it was unclear how MLL-ELL exerts its oncogenic properties, as it was reported that an artificial MLL-EAF1 fusion immortalized HPCs (<xref ref-type="bibr" rid="bib26">Luo et al., 2001</xref>). AF4 and EAF family proteins share structural similarities, both of which have the SDE motif and are shown to bind to SL1 (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>; <xref ref-type="bibr" rid="bib38">Okuda et al., 2016</xref>). We previously demonstrated that the combination of SDE and NKW motifs is required for transcriptional activation (<xref ref-type="bibr" rid="bib37">Okuda et al., 2015</xref>). Because EAF1 does not have an NKW motif, EAF1 is incompetent for transcriptional activation, and therefore MTMh-EAF1-C did not transform HPCs (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Instead, EAF1 homodimerizes through its EHD. The MTMT-EHD fusion (e.g., MTMTh-EAF1-N) transformed HPCs in a THD2-dependent manner, similar to MLL-AF6, which is known to transform HPCs via homodimerization (<xref ref-type="bibr" rid="bib24">Liedtke et al., 2010</xref>). Thus, we concluded that MLL-EAF1 transforms HPCs via homodimerization. The S600A/K606T double mutation on ELL completely abrogated the interaction with EAF1, while retaining some binding capacity to AF4 and did not impair MLL-ELL-mediated transformation. Thus, we concluded that MLL-ELL transforms HPCs via association with AF4 family proteins, but not with EAF1 (<xref ref-type="fig" rid="fig8">Figure 8D</xref>).</p><p>ChIP-qPCR analysis indicated that ELL recruited AF4 and ENL to the target chromatin but was unable to further recruit SL1 and MED26 (<xref ref-type="fig" rid="fig5">Figure 5D</xref>), suggesting that the AEP complex must dissociate from ELL to function as a transcriptional activator (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Thus, MLL-ELL is a loading factor of the AEP complex, but not a nucleating factor (like MLL-ENL). In our previous study, we showed that MLL-AF10 is also an AEP loading factor that loads ENL onto chromatin (<xref ref-type="bibr" rid="bib39">Okuda et al., 2017</xref>). It remains unclear how MLL-AF6, a dimer type of MLL fusion, affects the function of AEP and transforms HPCs. Nonetheless, ChIP-qPCR analysis showed that MLL-AF6 colocalized with AEP components at its target promoters (<xref ref-type="bibr" rid="bib64">Yokoyama et al., 2010</xref>), suggesting that MLL-AF6 also loads AEP to the target chromatin via unknown mechanisms. All of the presumed AEP loading factor type MLL fusions (i.e., MLL-ELL, MLL-AF10, and MLL-AF6) showed susceptibility to <italic>Mllt1</italic> knockdown, whereas the AEP nucleating factor type MLL fusions (e.g., MLL-ENL) were relatively resistant (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>; <xref ref-type="bibr" rid="bib39">Okuda et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">Yokoyama et al., 2010</xref>). Moreover, the AEP loading factor type MLL fusions exhibited relatively strong dependency on THD2, which mediates HBO1 complex recruitment (<xref ref-type="fig" rid="fig1">Figure 1</xref>). These results suggest that the HBO1 complex promotes loading of the AEP complex onto target chromatin (<xref ref-type="fig" rid="fig8">Figure 8D</xref>). Hence, the inhibitors that interfere with the MLL-HBO complex interaction may be highly effective for the AEP loading factor type MLL fusions.</p><p>Like MLL, NUP98 fuses with a variety of partners (<xref ref-type="bibr" rid="bib12">Gough et al., 2011</xref>). NUP98 fusion partners can be roughly subdivided into three groups: the homeodomain-containing protein type (e.g., NUP98-HOXA9), the chromatin reader type (e.g., NUP98-HBO1, -LEDGF, -MLL, -NSD1, -PHF23, -BPTF, and -KDM5A), and the coiled-coil structure containing protein type. Among the chromatin reader type NUP98 fusions, MLL and LEDGF are components of the MLL complex (<xref ref-type="bibr" rid="bib65">Yokoyama and Cleary, 2008</xref>), which targets previously transcribed CpG-rich promoters through association with unmethylated CpGs, di/tri-methylated histone H3 lysine 36 (H3K36me2/3) (<xref ref-type="bibr" rid="bib36">Okuda et al., 2014</xref>), and di/tri-methylated histone H3 lysine 4 (H3K4me2/3) recognized by the PHD finger 3 of MLL (<xref ref-type="bibr" rid="bib30">Milne et al., 2010</xref>; <xref ref-type="bibr" rid="bib58">Wang et al., 2010</xref>). NUP98-NSD1 was shown to activate HOX-A genes through the association with methylated H3K36 marks (<xref ref-type="bibr" rid="bib57">Wang et al., 2007</xref>), and NUP98-PHF23, -BPTF, and-KDM5A were through association with H3K4me2/3 marks (<xref ref-type="bibr" rid="bib67">Zhang et al., 2020</xref>). Thus, the chromatin reader type NUP98 fusions confer a targeting ability to the chromatin of the HOX-A loci by interacting with specific chromatin modifications or chromatin-binding proteins. A subset of NUP98 fusions including NUP98-HBO1 and -LEDGF appear to target through interaction with MLL at least in part. This was supported by the immortalization of HPCs by the artificial fusion of NUP98 and MENIN (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). It has been reported that a portion of MLL target genes is regulated in a MENIN-independent manner (<xref ref-type="bibr" rid="bib1">Artinger et al., 2013</xref>) and an MLL mutant protein lacking the MENIN-binding motif but retaining the CXXC domain and the PHD finger 3 localized at the <italic>HOXA9</italic> locus presumably through the association with unmethylated CpGs and H3K4me2/3 (<xref ref-type="bibr" rid="bib30">Milne et al., 2010</xref>; <xref ref-type="bibr" rid="bib58">Wang et al., 2010</xref>), suggesting that MLL can bind to some of its target chromatin in a MENIN-independent manner. The NUP98-MLL fusion protein expressed in leukemia patients does not retain the structures responsible for interaction with MENIN and LEDGF (<xref ref-type="bibr" rid="bib15">Kaltenbach et al., 2010</xref>), suggesting that the MLL portion in NUP98-MLL confers its targeting ability in a MENIN-independent manner. The proliferation of NUP98-HBO1-ICs was dependent on MLL (<xref ref-type="fig" rid="fig7">Figure 7E</xref>) and was slowed but not entirely blocked by the MENIN-MLL interaction inhibitor (<xref ref-type="fig" rid="fig7">Figure 7F</xref>). These results indicate that a MENIN-less MLL complex may sufficiently recruit NUP98-HBO1 possibly through the association with H3K4me3 marks via the PHD finger 3 of MLL. The presence of H3K4me3 marks at the target promoter is also a prerequisite for the HBO1 complex-MLL association on chromatin as they are recognized by the PHD finger of ING4/5 subunits (<xref ref-type="fig" rid="fig3">Figure 3F</xref> and <xref ref-type="fig" rid="fig8">Figure 8C</xref>; <xref ref-type="bibr" rid="bib6">Champagne et al., 2008</xref>). Taken together, these results suggest that a subset of NUP98 fusions target the HOX-A loci via association with MLL and H3K4me3 marks and activate transcription by NUP98-mediated functions (<xref ref-type="fig" rid="fig8">Figure 8D</xref>).</p><p>This study demonstrated that various MLL fusions and NUP98 fusions transform HPCs via HBO1-MLL interaction (<xref ref-type="fig" rid="fig8">Figure 8D</xref>). Hence, we propose that the binding modules in this interaction can be a good molecular target for drug development. HBO1-MLL interaction inhibitors would complement the therapeutic effects of the emerging MENIN-MLL interaction inhibitors (<xref ref-type="bibr" rid="bib16">Klossowski et al., 2019</xref>; <xref ref-type="bibr" rid="bib18">Krivtsov et al., 2019</xref>) to treat malignant leukemia with subsets of MLL and NUP98 fusions.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Materials availability</title><p>Materials generated in this study will be provided upon request.</p></sec><sec id="s4-2"><title>Experimental model and subject details</title><sec id="s4-2-1"><title>Vector constructs</title><p>For protein expression vectors, cDNAs obtained from Kazusa Genome Technologies Inc (<xref ref-type="bibr" rid="bib35">Nagase et al., 2008</xref>) were modified by PCR-mediated mutagenesis and cloned into the pMSCV vector (for virus production) or pCMV5 vector (for transient expression) by restriction enzyme digestion and DNA ligation. The MSCV-neo MLL-ENL and MLL-AF10 vectors have been previously described (<xref ref-type="bibr" rid="bib39">Okuda et al., 2017</xref>). sgRNA expression vectors were constructed using the pLKO5.sgRNA.EFS.GFP vector (<xref ref-type="bibr" rid="bib14">Heckl et al., 2014</xref>). shRNA expression vectors were constructed using a pLKO.1 vector or were purchased from Dharmacon. The target sequences of sgRNA are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a and b</xref>.</p></sec><sec id="s4-2-2"><title>Cell lines</title><p>HEK293T cells were a gift from Michael Cleary and were authenticated by the JCRB Cell Bank in 2019. HEK293TN cells were purchased from System Biosciences. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin (PS). The Platinum-E (PLAT-E) ecotropic virus-packaging cell line—a gift from Toshio Kitamura (<xref ref-type="bibr" rid="bib34">Morita et al., 2000</xref>)—was cultured in DMEM supplemented with 10% FBS, puromycin, blasticidin, and PS. The human leukemia cell lines HB1119 and REH, gifts from Michael Cleary (<xref ref-type="bibr" rid="bib53">Tkachuk et al., 1992</xref>), were cultured in RPMI 1640 medium supplemented with 10% FBS and PS. HEK293T–LUC cells were generated by transduction of the lentivirus carrying pLKO1-puro-FR-LUC, as described previously (<xref ref-type="bibr" rid="bib37">Okuda et al., 2015</xref>). Murine myeloid progenitors immortalized by various transgenes were cultured in RPMI 1640 medium supplemented with 10% FBS, and PS containing murine stem cell factors (mSCFs), murine interleukin-3 (mIL-3), and murine granulocyte-macrophage colony-stimulating factor (mGM-CSF; 1 ng/mL of each). Cells were cultured in the incubator at 37°C and 5% CO<sub>2</sub> and routinely tested for mycoplasma using the MycoAlert Mycoplasma detection kit (Lonza).</p></sec><sec id="s4-2-3"><title>Western blotting</title><p>Western blotting was performed as previously described (<xref ref-type="bibr" rid="bib61">Yokoyama et al., 2002</xref>). Briefly, proteins were separated electrophoretically in an acrylamide gel and were transblotted onto nitrocellulose sheets using a mini transblot cell (Bio-Rad). The nitrocellulose sheets were blocked with 5% skimmed milk in T-PBS (phosphate-buffered saline containing 0.1% Tween 20) for 1 hr, rinsed twice with T-PBS, and incubated with primary antibodies suspended in 5% skim milk in T-PBS overnight. The blots were then washed twice with T-PBS and incubated with peroxidase-conjugated secondary antibodies for 2 hr. Chemiluminescence was performed using the ECL chemiluminescence reagent (GE Healthcare). The antibodies used in this study are listed in Key resources table.</p></sec><sec id="s4-2-4"><title>Virus production</title><p>Ecotropic retrovirus was produced using PLAT-E packaging cells (<xref ref-type="bibr" rid="bib34">Morita et al., 2000</xref>). Lentiviruses were produced in HEK293TN cells using the pMDLg/pRRE, pRSV-rev, and pMD2.G vectors, all of which were gifts from Didier Trono (<xref ref-type="bibr" rid="bib8">Dull et al., 1998</xref>). The virus-containing medium was harvested 24–48 hr following transfection and used for viral transduction.</p></sec></sec><sec id="s4-3"><title>Myeloid progenitor transformation assay</title><p>The myeloid progenitor transformation assay was carried out as previously described (<xref ref-type="bibr" rid="bib21">Lavau et al., 1997</xref>; <xref ref-type="bibr" rid="bib41">Okuda and Yokoyama, 2017b</xref>). Bone marrow cells were harvested from the femurs and tibiae of 5-week-old female C57BL/6J mice. c-Kit-positive cells were enriched using magnetic beads conjugated with an anti-c-Kit antibody (Miltenyi Biotec), transduced with a recombinant retrovirus by spinoculation, and then plated (4 × 10<sup>4</sup> cells/sample) in a methylcellulose medium (Iscove’s modified Dulbecco’s medium, 20% FBS, 1.6% methylcellulose, and 100 µM β-mercaptoethanol) containing mSCF, mIL-3, and mGM-CSF (10 ng/mL each). During the first culture passage, G418 (1 mg/mL) or puromycin (1 µg/mL) was added to the culture medium to select the transduced cells. <italic>Hoxa9</italic> expression was quantified by qRT-PCR after the first passage. Cells were then re-plated once every 5 days with fresh medium. Colony-forming units were quantified per 10<sup>4</sup> plated cells at each passage.</p></sec><sec id="s4-4"><title>In vivo leukemogenesis assay</title><p>In vivo leukemogenesis assay was carried out as previously described (<xref ref-type="bibr" rid="bib21">Lavau et al., 1997</xref>; <xref ref-type="bibr" rid="bib40">Okuda and Yokoyama, 2017a</xref>). Cells positive for c-Kit (2 × 10<sup>5</sup>), prepared from mouse femurs and tibiae, were transduced with retrovirus by spinoculation and intravenously transplanted into sublethally irradiated (5–6 Gy) 8-week-old female C57BL/6JJcl (C57BL/6J) mice. Moribund mice were euthanized, and the cells isolated from their bone marrow were cultured in methylcellulose medium used for myeloid progenitor transformation assays for more than three passages to remove untransformed cells and then subjected to secondary transplantation. For secondary leukemia, leukemia cells (2 × 10<sup>5</sup>) cultured ex vivo were transplanted in the same manner as the primary transplantation. This protocol was approved by the National Cancer Center Institutional Animal Care and Use Committee.</p></sec><sec id="s4-5"><title>qRT-PCR</title><p>Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and reverse-transcribed using the Superscript III First Strand cDNA Synthesis System (Thermo Fisher Scientific) with oligo (dT) primers. Gene expression was analyzed by qPCR using TaqMan probes (Thermo Fisher Scientific). Relative expression levels were normalized to those of <italic>GAPDH</italic>/<italic>Gapdh</italic> and determined using a standard curve and the relative quantification method, according to the manufacturer’s instructions (Thermo Fisher Scientific). Commercially available PCR probe sets used in this study are listed in Key resources table.</p></sec><sec id="s4-6"><title>Fractionation-assisted chromatin immunoprecipitation</title><p>Chromatin fractions from HEK293T and HB1119 cells were prepared using the fanChIP method, as described previously (<xref ref-type="bibr" rid="bib33">Miyamoto and Yokoyama, 2021</xref>; <xref ref-type="bibr" rid="bib36">Okuda et al., 2014</xref>). Cells were suspended in CSK buffer (100 mM NaCl, 10 mM PIPES [pH 6.8], 3 mM MgCl<sub>2</sub>, 1 mM EGTA, 0.3 M sucrose, 0.5% Triton X-100, 5 mM sodium butyrate, 0.5 mM DTT, and protease inhibitor cocktail) and centrifuged (400× <italic>g</italic> for 5 min, at 4°C) to remove the soluble fraction. The pellet was resuspended in MNase buffer (50 mM Tris-HCl [pH 7.5], 4 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 0.3 M sucrose, 5 mM sodium butyrate, 0.5 mM DTT, and protease inhibitor cocktail) and treated with MNase at 37°C for 3–6 min to obtain oligonucleosomes. MNase reaction was then stopped by adding EDTA (pH 8.0) to a final concentration of 20 mM. An equal amount of lysis buffer (250 mM NaCl, 20 mM sodium phosphate [pH 7.0], 30 mM sodium pyrophosphate, 5 mM EDTA, 10 mM NaF, 0.1% NP-40, 10% glycerol, 1 mM DTT, and EDTA-free protease inhibitor cocktail) was added to increase solubility. The chromatin fraction was cleared by centrifugation (15,000 rpm for 5 min, 4°C) and subjected to immunoprecipitation with specific antibodies and Protein-G magnetic microbeads (Invitrogen) or with anti-FLAG M2 antibody-conjugated beads (Key resource table). Immunoprecipitates were then washed five times with washing buffer (1:1 mixture of lysis buffer and MNase buffer with 20 mM EDTA) and eluted in elution buffer (1% SDS and 50 mM NaHCO<sub>3</sub>). The eluted material was analyzed by multiple methods including western blotting, qPCR, and deep sequencing. Optionally, the immunoprecipitates were washed twice with washing buffer, twice with MNase buffer, and then treated with DNase I (Qiagen) for 15 min at room temperature. The immunoprecipitates were further washed four times with washing buffer and eluted using elution buffer. The eluted materials were subjected to western blotting and SYBR green staining.</p></sec><sec id="s4-7"><title>ChIP-qPCR and ChIP-seq</title><p>The eluted material obtained by fanChIP was extracted using phenol/chloroform/isoamyl alcohol. DNA was precipitated with glycogen, dissolved in TE buffer, and analyzed by qPCR (ChIP-qPCR) or deep sequencing (ChIP-seq). The qPCR probe/primer sequences are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>. For deep sequencing, DNA was further fragmented (~150 bp) using the Covaris M220 DNA shearing system (M and M Instruments Inc). Deep sequencing was then performed using the TruSeq ChIP Sample Prep Kit (Illumina) and HiSeq2500 (Illumina) at the core facility of Hiroshima University. Data were visualized using Integrative Genome Viewer (The Broad Institute). Raw reads in FASTQ format were trimmed using Cutadapt and aligned to the reference genome hg19 with BWA (<xref ref-type="bibr" rid="bib23">Li and Durbin, 2009</xref>; <xref ref-type="bibr" rid="bib28">Martin, 2011</xref>). Accession numbers and sample IDs are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>.</p></sec><sec id="s4-8"><title>Liquid chromatography-tandem mass spectrometry analysis</title><p>Proteins were digested with trypsin and tandem mass spectrometry was performed using an LTQ Orbitrap ELITE ETD mass spectrometer (Thermo Fisher Scientific), as described previously (<xref ref-type="bibr" rid="bib39">Okuda et al., 2017</xref>).</p></sec><sec id="s4-9"><title>sgRNA competition assay</title><p><italic>Cas9</italic> was introduced via lentiviral transduction using the pKLV2-EF1a-Cas9Bsd-W vector (<xref ref-type="bibr" rid="bib54">Tzelepis et al., 2016</xref>). Cas9-expressing stable lines were established with blasticidin (10–30 µg/mL) selection. The sequences of sgRNAs are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a and b</xref>. The targeting sgRNA was co-expressed with GFP via lentiviral transduction using pLKO5.sgRNA.EFS.GFP vector (<xref ref-type="bibr" rid="bib14">Heckl et al., 2014</xref>). Percentages of GFP-positive cells were initially determined by FACS analysis at 2 days after sgRNA transduction and then measured every 4 days.</p></sec><sec id="s4-10"><title>Accession numbers</title><p>Deep sequencing data used in this study have been deposited in the DNA Data Bank of Japan (DDBJ) Sequence Read Archive under the accession numbers listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref> (ChIP-seq, CIRA-seq, and RNA-seq). The mass spectrometry data were deposited to Japan ProteOme STandard Repository (jPOSTrepo) under the accession number JPST001262 (PXID:PXD027400).</p></sec><sec id="s4-11"><title>Statistics</title><p>Statistical analysis was performed using GraphPad Prism7 software. Data are presented as the mean with standard deviation. Multiple comparisons were performed by two-way ANOVA. The statistical tests were two-sided. Mice transplantation experiments were analyzed by the log-rank test and Bonferroni correction was applied for multiple comparisons. p-values &lt; 0.05 were considered statistically significant. n.s.: p &gt; 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001.</p></sec><sec id="s4-12"><title>Study approval</title><p>All animal experimental protocols were approved by the National Cancer Center (Tokyo, Japan) Institutional Animal Care and Use Committee (T17501).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Ikuko Yokoyama, Hagumu Sato, Kanae Ito, Makiko Okuda, Yuzo Sato, Megumi Nakamura, Etsuko Kanai, Aya Nakayama, and Ayako Yokoyama for technical assistance. We also thank the Shonai Regional Industry Promotion Center members for their administrative support. This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI grants (16H05337, 19H03694 to AY). This work was also supported in part by research funds from the Yamagata prefectural government, the City of Tsuruoka, Dainippon Sumitomo Pharma Co. Ltd., and the Friends of Leukemia Research Fund.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>A.Y. received a research grant from Dainippon Sumitomo Pharma Co. Ltd.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Data curation, Software, Formal analysis, Visualization, Methodology</p></fn><fn fn-type="con" id="con3"><p>Resources, Formal analysis, Validation</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Visualization</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Visualization, Methodology</p></fn><fn fn-type="con" id="con7"><p>Resources, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con8"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con9"><p>Supervision</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experimental protocols were approved by the National Cancer Center (Tokyo Japan) Institutional Animal Care and Use Committee.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Gel images.</title></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-65872-data1-v1.pdf"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Sequence data.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-65872-supp1-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-65872-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>ChIP-seq data, CIRA-seq data, and RNA-seq data have been deposited at the DDBJ (DNA Data Bank of Japan) Sequence Read Archive under the accession numbers (DRA010818, DRA004871, DRA004872, DRA010819, DRA008732, DRA008734, and DRA004874) and sample IDs listed in Supplementary file 1.The mass spectrometry data were deposited to Japan ProteOme STandard Repository (jPOSTrepo) under the accession number JPST001262 (PXID:PXD027400).</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>HIROSHIMA</collab></person-group><year iso-8601-date="2020">2020</year><data-title>Genomic localization of various factors/modifications in HB1119 cells</data-title><source>DDBJ</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://ddbj.nig.ac.jp/public/ddbj_database/dra/fastq/DRA010/DRA010818/">DRA010818</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>HIROSHIMA</collab></person-group><year iso-8601-date="2020">2020</year><data-title>Genomic localization of various FLAG-tagged proteins in HEK293T cells</data-title><source>DDBJ</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://ddbj.nig.ac.jp/public/ddbj_database/dra/fastq/DRA010/DRA010819/">DRA010819</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>HIROSHIMA</collab></person-group><year iso-8601-date="2021">2021</year><data-title>Genomic localization of various proteins in HB1119 cells</data-title><source>DDBJ</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://ddbj.nig.ac.jp/public/ddbj_database/dra/fastq/DRA012/DRA012472/">DRA012472</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>HIROSHIMA</collab></person-group><year iso-8601-date="2021">2021</year><data-title>Genomic localization of various proteins in HEK293T cells</data-title><source>DDBJ</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://ddbj.nig.ac.jp/public/ddbj_database/dra/fastq/DRA012/DRA012473/">DRA012473</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset5" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>HIROSHIMA</collab></person-group><year iso-8601-date="2016">2016</year><data-title>Genomic localization of various factors/modificaions in HB1119 cells</data-title><source>DDBJ</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://ddbj.nig.ac.jp/public/ddbj_database/dra/fastq/DRA004/DRA004871/">DRA004871</pub-id></element-citation></p><p><element-citation id="dataset6" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>HIROSHIMA</collab></person-group><year iso-8601-date="2016">2016</year><data-title>Genomic localization of various factors/modificaions in 293T cells</data-title><source>DDBJ</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://ddbj.nig.ac.jp/public/ddbj_database/dra/fastq/DRA004/DRA004872/">DRA004872</pub-id></element-citation></p><p><element-citation id="dataset7" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>HIROSHIMA</collab></person-group><year iso-8601-date="2019">2019</year><data-title>Expression profiles of HB1119 and 293T cell lines</data-title><source>DDBJ</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://ddbj.nig.ac.jp/public/ddbj_database/dra/fastq/DRA004/DRA004874/">DRA004874</pub-id></element-citation></p><p><element-citation id="dataset8" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>HIROSHIMA</collab></person-group><year iso-8601-date="2019">2019</year><data-title>ChIP-seq analysis of HEK293T cell lines</data-title><source>DDBJ</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://ddbj.nig.ac.jp/public/ddbj_database/dra/fastq/DRA008/DRA008732/">DRA008732</pub-id></element-citation></p><p><element-citation id="dataset9" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>HIROSHIMA</collab></person-group><year iso-8601-date="2019">2019</year><data-title>CIRA-seq analysis of the HEK293T cell line</data-title><source>DDBJ</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://ddbj.nig.ac.jp/public/ddbj_database/dra/fastq/DRA008/DRA008734/">DRA008734</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artinger</surname> <given-names>EL</given-names></name><name><surname>Mishra</surname> <given-names>BP</given-names></name><name><surname>Zaffuto</surname> <given-names>KM</given-names></name><name><surname>Li</surname> <given-names>BE</given-names></name><name><surname>Chung</surname> <given-names>EK</given-names></name><name><surname>Moore</surname> <given-names>AW</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Cheng</surname> <given-names>C</given-names></name><name><surname>Ernst</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>An MLL-dependent network sustains hematopoiesis</article-title><source>PNAS</source><volume>110</volume><fpage>12000</fpage><lpage>12005</lpage><pub-id pub-id-type="doi">10.1073/pnas.1301278110</pub-id><pub-id pub-id-type="pmid">23744037</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au</surname> <given-names>YZ</given-names></name><name><surname>Gu</surname> <given-names>M</given-names></name><name><surname>De Braekeleer</surname> <given-names>E</given-names></name><name><surname>Gozdecka</surname> <given-names>M</given-names></name><name><surname>Aspris</surname> <given-names>D</given-names></name><name><surname>Tarumoto</surname> <given-names>Y</given-names></name><name><surname>Cooper</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Ong</surname> <given-names>SH</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Tzelepis</surname> <given-names>K</given-names></name><name><surname>Huntly</surname> <given-names>BJP</given-names></name><name><surname>Vassiliou</surname> <given-names>G</given-names></name><name><surname>Yusa</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements</article-title><source>Leukemia</source><volume>35</volume><fpage>1012</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1038/s41375-020-1001-z</pub-id><pub-id pub-id-type="pmid">32764680</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avvakumov</surname> <given-names>N</given-names></name><name><surname>Lalonde</surname> <given-names>ME</given-names></name><name><surname>Saksouk</surname> <given-names>N</given-names></name><name><surname>Paquet</surname> <given-names>E</given-names></name><name><surname>Glass</surname> <given-names>KC</given-names></name><name><surname>Landry</surname> <given-names>AJ</given-names></name><name><surname>Doyon</surname> <given-names>Y</given-names></name><name><surname>Cayrou</surname> <given-names>C</given-names></name><name><surname>Robitaille</surname> <given-names>GA</given-names></name><name><surname>Richard</surname> <given-names>DE</given-names></name><name><surname>Yang</surname> <given-names>XJ</given-names></name><name><surname>Kutateladze</surname> <given-names>TG</given-names></name><name><surname>Côté</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Conserved molecular interactions within the HBO1 acetyltransferase complexes regulate cell proliferation</article-title><source>Molecular and Cellular Biology</source><volume>32</volume><fpage>689</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1128/MCB.06455-11</pub-id><pub-id pub-id-type="pmid">22144582</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayton</surname> <given-names>PM</given-names></name><name><surname>Chen</surname> <given-names>EH</given-names></name><name><surname>Cleary</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Binding to nonmethylated CpG DNA is essential for target recognition, Transactivation, and myeloid transformation by an MLL oncoprotein</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>10470</fpage><lpage>10478</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.23.10470-10478.2004</pub-id><pub-id pub-id-type="pmid">15542854</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birke</surname> <given-names>M</given-names></name><name><surname>Schreiner</surname> <given-names>S</given-names></name><name><surname>García-Cuéllar</surname> <given-names>MP</given-names></name><name><surname>Mahr</surname> <given-names>K</given-names></name><name><surname>Titgemeyer</surname> <given-names>F</given-names></name><name><surname>Slany</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation</article-title><source>Nucleic Acids Research</source><volume>30</volume><fpage>958</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1093/nar/30.4.958</pub-id><pub-id pub-id-type="pmid">11842107</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Champagne</surname> <given-names>KS</given-names></name><name><surname>Saksouk</surname> <given-names>N</given-names></name><name><surname>Peña</surname> <given-names>PV</given-names></name><name><surname>Johnson</surname> <given-names>K</given-names></name><name><surname>Ullah</surname> <given-names>M</given-names></name><name><surname>Yang</surname> <given-names>XJ</given-names></name><name><surname>Côté</surname> <given-names>J</given-names></name><name><surname>Kutateladze</surname> <given-names>TG</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The crystal structure of the ING5 PHD finger in complex with an H3K4me3 histone peptide</article-title><source>Proteins: Structure, Function, and Bioinformatics</source><volume>72</volume><fpage>1371</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1002/prot.22140</pub-id><pub-id pub-id-type="pmid">18623064</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiMartino</surname> <given-names>JF</given-names></name><name><surname>Miller</surname> <given-names>T</given-names></name><name><surname>Ayton</surname> <given-names>PM</given-names></name><name><surname>Landewe</surname> <given-names>T</given-names></name><name><surname>Hess</surname> <given-names>JL</given-names></name><name><surname>Cleary</surname> <given-names>ML</given-names></name><name><surname>Shilatifard</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL</article-title><source>Blood</source><volume>96</volume><fpage>3887</fpage><lpage>3893</lpage><pub-id pub-id-type="doi">10.1182/blood.V96.12.3887</pub-id><pub-id pub-id-type="pmid">11090074</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dull</surname> <given-names>T</given-names></name><name><surname>Zufferey</surname> <given-names>R</given-names></name><name><surname>Kelly</surname> <given-names>M</given-names></name><name><surname>Mandel</surname> <given-names>RJ</given-names></name><name><surname>Nguyen</surname> <given-names>M</given-names></name><name><surname>Trono</surname> <given-names>D</given-names></name><name><surname>Naldini</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A third-generation Lentivirus vector with a conditional packaging system</article-title><source>Journal of Virology</source><volume>72</volume><fpage>8463</fpage><lpage>8471</lpage><pub-id pub-id-type="doi">10.1128/JVI.72.11.8463-8471.1998</pub-id><pub-id pub-id-type="pmid">9765382</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erb</surname> <given-names>MA</given-names></name><name><surname>Scott</surname> <given-names>TG</given-names></name><name><surname>Li</surname> <given-names>BE</given-names></name><name><surname>Xie</surname> <given-names>H</given-names></name><name><surname>Paulk</surname> <given-names>J</given-names></name><name><surname>Seo</surname> <given-names>HS</given-names></name><name><surname>Souza</surname> <given-names>A</given-names></name><name><surname>Roberts</surname> <given-names>JM</given-names></name><name><surname>Dastjerdi</surname> <given-names>S</given-names></name><name><surname>Buckley</surname> <given-names>DL</given-names></name><name><surname>Sanjana</surname> <given-names>NE</given-names></name><name><surname>Shalem</surname> <given-names>O</given-names></name><name><surname>Nabet</surname> <given-names>B</given-names></name><name><surname>Zeid</surname> <given-names>R</given-names></name><name><surname>Offei-Addo</surname> <given-names>NK</given-names></name><name><surname>Dhe-Paganon</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Orkin</surname> <given-names>SH</given-names></name><name><surname>Winter</surname> <given-names>GE</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transcription control by the ENL YEATS domain in acute leukaemia</article-title><source>Nature</source><volume>543</volume><fpage>270</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1038/nature21688</pub-id><pub-id pub-id-type="pmid">28241139</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foy</surname> <given-names>RL</given-names></name><name><surname>Song</surname> <given-names>IY</given-names></name><name><surname>Chitalia</surname> <given-names>VC</given-names></name><name><surname>Cohen</surname> <given-names>HT</given-names></name><name><surname>Saksouk</surname> <given-names>N</given-names></name><name><surname>Cayrou</surname> <given-names>C</given-names></name><name><surname>Vaziri</surname> <given-names>C</given-names></name><name><surname>Côté</surname> <given-names>J</given-names></name><name><surname>Panchenko</surname> <given-names>MV</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Role of Jade-1 in the histone acetyltransferase (HAT) HBO1 complex</article-title><source>Journal of Biological Chemistry</source><volume>283</volume><fpage>28817</fpage><lpage>28826</lpage><pub-id pub-id-type="doi">10.1074/jbc.M801407200</pub-id><pub-id pub-id-type="pmid">18684714</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodfellow</surname> <given-names>SJ</given-names></name><name><surname>Zomerdijk</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Basic mechanisms in RNA polymerase I transcription of the ribosomal RNA genes</article-title><source>Sub-Cellular Biochemistry</source><volume>61</volume><fpage>211</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1007/978-94-007-4525-4_10</pub-id><pub-id pub-id-type="pmid">23150253</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gough</surname> <given-names>SM</given-names></name><name><surname>Slape</surname> <given-names>CI</given-names></name><name><surname>Aplan</surname> <given-names>PD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights</article-title><source>Blood</source><volume>118</volume><fpage>6247</fpage><lpage>6257</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-07-328880</pub-id><pub-id pub-id-type="pmid">21948299</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname> <given-names>Y</given-names></name><name><surname>Harada</surname> <given-names>Y</given-names></name><name><surname>Kagiyama</surname> <given-names>Y</given-names></name><name><surname>Nishikawa</surname> <given-names>S</given-names></name><name><surname>Ding</surname> <given-names>Y</given-names></name><name><surname>Imagawa</surname> <given-names>J</given-names></name><name><surname>Shingai</surname> <given-names>N</given-names></name><name><surname>Kato</surname> <given-names>N</given-names></name><name><surname>Kitaura</surname> <given-names>J</given-names></name><name><surname>Hokaiwado</surname> <given-names>S</given-names></name><name><surname>Maemoto</surname> <given-names>Y</given-names></name><name><surname>Ito</surname> <given-names>A</given-names></name><name><surname>Matsui</surname> <given-names>H</given-names></name><name><surname>Kitabayashi</surname> <given-names>I</given-names></name><name><surname>Iwama</surname> <given-names>A</given-names></name><name><surname>Komatsu</surname> <given-names>N</given-names></name><name><surname>Kitamura</surname> <given-names>T</given-names></name><name><surname>Harada</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>NUP98-HBO1-fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis</article-title><source>Blood Advances</source><volume>3</volume><fpage>1047</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2018025007</pub-id><pub-id pub-id-type="pmid">30944097</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heckl</surname> <given-names>D</given-names></name><name><surname>Kowalczyk</surname> <given-names>MS</given-names></name><name><surname>Yudovich</surname> <given-names>D</given-names></name><name><surname>Belizaire</surname> <given-names>R</given-names></name><name><surname>Puram</surname> <given-names>RV</given-names></name><name><surname>McConkey</surname> <given-names>ME</given-names></name><name><surname>Thielke</surname> <given-names>A</given-names></name><name><surname>Aster</surname> <given-names>JC</given-names></name><name><surname>Regev</surname> <given-names>A</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing</article-title><source>Nature Biotechnology</source><volume>32</volume><fpage>941</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1038/nbt.2951</pub-id><pub-id pub-id-type="pmid">24952903</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaltenbach</surname> <given-names>S</given-names></name><name><surname>Soler</surname> <given-names>G</given-names></name><name><surname>Barin</surname> <given-names>C</given-names></name><name><surname>Gervais</surname> <given-names>C</given-names></name><name><surname>Bernard</surname> <given-names>OA</given-names></name><name><surname>Penard-Lacronique</surname> <given-names>V</given-names></name><name><surname>Romana</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>NUP98-MLL fusion in human acute myeloblastic leukemia</article-title><source>Blood</source><volume>116</volume><fpage>2332</fpage><lpage>2335</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-04-277806</pub-id><pub-id pub-id-type="pmid">20558618</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klossowski</surname> <given-names>S</given-names></name><name><surname>Miao</surname> <given-names>H</given-names></name><name><surname>Kempinska</surname> <given-names>K</given-names></name><name><surname>Wu</surname> <given-names>T</given-names></name><name><surname>Purohit</surname> <given-names>T</given-names></name><name><surname>Kim</surname> <given-names>E</given-names></name><name><surname>Linhares</surname> <given-names>BM</given-names></name><name><surname>Chen</surname> <given-names>D</given-names></name><name><surname>Jih</surname> <given-names>G</given-names></name><name><surname>Perkey</surname> <given-names>E</given-names></name><name><surname>Huang</surname> <given-names>H</given-names></name><name><surname>He</surname> <given-names>M</given-names></name><name><surname>Wen</surname> <given-names>B</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Yu</surname> <given-names>K</given-names></name><name><surname>Lee</surname> <given-names>SC-W</given-names></name><name><surname>Danet-Desnoyers</surname> <given-names>G</given-names></name><name><surname>Trotman</surname> <given-names>W</given-names></name><name><surname>Kandarpa</surname> <given-names>M</given-names></name><name><surname>Cotton</surname> <given-names>A</given-names></name><name><surname>Abdel-Wahab</surname> <given-names>O</given-names></name><name><surname>Lei</surname> <given-names>H</given-names></name><name><surname>Dou</surname> <given-names>Y</given-names></name><name><surname>Guzman</surname> <given-names>M</given-names></name><name><surname>Peterson</surname> <given-names>L</given-names></name><name><surname>Gruber</surname> <given-names>T</given-names></name><name><surname>Choi</surname> <given-names>S</given-names></name><name><surname>Sun</surname> <given-names>D</given-names></name><name><surname>Ren</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>L-S</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Burrows</surname> <given-names>F</given-names></name><name><surname>Maillard</surname> <given-names>I</given-names></name><name><surname>Cierpicki</surname> <given-names>T</given-names></name><name><surname>Grembecka</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia</article-title><source>Journal of Clinical Investigation</source><volume>130</volume><fpage>981</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1172/JCI129126</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krivtsov</surname> <given-names>AV</given-names></name><name><surname>Twomey</surname> <given-names>D</given-names></name><name><surname>Feng</surname> <given-names>Z</given-names></name><name><surname>Stubbs</surname> <given-names>MC</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Faber</surname> <given-names>J</given-names></name><name><surname>Levine</surname> <given-names>JE</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name><name><surname>Gilliland</surname> <given-names>DG</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9</article-title><source>Nature</source><volume>442</volume><fpage>818</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1038/nature04980</pub-id><pub-id pub-id-type="pmid">16862118</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krivtsov</surname> <given-names>AV</given-names></name><name><surname>Evans</surname> <given-names>K</given-names></name><name><surname>Gadrey</surname> <given-names>JY</given-names></name><name><surname>Eschle</surname> <given-names>BK</given-names></name><name><surname>Hatton</surname> <given-names>C</given-names></name><name><surname>Uckelmann</surname> <given-names>HJ</given-names></name><name><surname>Ross</surname> <given-names>KN</given-names></name><name><surname>Perner</surname> <given-names>F</given-names></name><name><surname>Olsen</surname> <given-names>SN</given-names></name><name><surname>Pritchard</surname> <given-names>T</given-names></name><name><surname>McDermott</surname> <given-names>L</given-names></name><name><surname>Jones</surname> <given-names>CD</given-names></name><name><surname>Jing</surname> <given-names>D</given-names></name><name><surname>Braytee</surname> <given-names>A</given-names></name><name><surname>Chacon</surname> <given-names>D</given-names></name><name><surname>Earley</surname> <given-names>E</given-names></name><name><surname>McKeever</surname> <given-names>BM</given-names></name><name><surname>Claremon</surname> <given-names>D</given-names></name><name><surname>Gifford</surname> <given-names>AJ</given-names></name><name><surname>Lee</surname> <given-names>HJ</given-names></name><name><surname>Teicher</surname> <given-names>BA</given-names></name><name><surname>Pimanda</surname> <given-names>JE</given-names></name><name><surname>Beck</surname> <given-names>D</given-names></name><name><surname>Perry</surname> <given-names>JA</given-names></name><name><surname>Smith</surname> <given-names>MA</given-names></name><name><surname>McGeehan</surname> <given-names>GM</given-names></name><name><surname>Lock</surname> <given-names>RB</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-Rearranged leukemia</article-title><source>Cancer Cell</source><volume>36</volume><fpage>660</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.11.001</pub-id><pub-id pub-id-type="pmid">31821784</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroon</surname> <given-names>E</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Mayotte</surname> <given-names>N</given-names></name><name><surname>Nakamura</surname> <given-names>T</given-names></name><name><surname>Sauvageau</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>NUP98-HOXA9 expression in Hemopoietic stem cells induces chronic and acute myeloid leukemias in mice</article-title><source>The EMBO Journal</source><volume>20</volume><fpage>350</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.3.350</pub-id><pub-id pub-id-type="pmid">11157742</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lalonde</surname> <given-names>ME</given-names></name><name><surname>Avvakumov</surname> <given-names>N</given-names></name><name><surname>Glass</surname> <given-names>KC</given-names></name><name><surname>Joncas</surname> <given-names>FH</given-names></name><name><surname>Saksouk</surname> <given-names>N</given-names></name><name><surname>Holliday</surname> <given-names>M</given-names></name><name><surname>Paquet</surname> <given-names>E</given-names></name><name><surname>Yan</surname> <given-names>K</given-names></name><name><surname>Tong</surname> <given-names>Q</given-names></name><name><surname>Klein</surname> <given-names>BJ</given-names></name><name><surname>Tan</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>XJ</given-names></name><name><surname>Kutateladze</surname> <given-names>TG</given-names></name><name><surname>Côté</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Exchange of associated factors directs a switch in HBO1 acetyltransferase histone tail specificity</article-title><source>Genes &amp; Development</source><volume>27</volume><fpage>2009</fpage><lpage>2024</lpage><pub-id pub-id-type="doi">10.1101/gad.223396.113</pub-id><pub-id pub-id-type="pmid">24065767</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavau</surname> <given-names>C</given-names></name><name><surname>Szilvassy</surname> <given-names>SJ</given-names></name><name><surname>Slany</surname> <given-names>R</given-names></name><name><surname>Cleary</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL</article-title><source>The EMBO Journal</source><volume>16</volume><fpage>4226</fpage><lpage>4237</lpage><pub-id pub-id-type="doi">10.1093/emboj/16.14.4226</pub-id><pub-id pub-id-type="pmid">9250666</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Wen</surname> <given-names>H</given-names></name><name><surname>Xi</surname> <given-names>Y</given-names></name><name><surname>Tanaka</surname> <given-names>K</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Peng</surname> <given-names>D</given-names></name><name><surname>Ren</surname> <given-names>Y</given-names></name><name><surname>Jin</surname> <given-names>Q</given-names></name><name><surname>Dent</surname> <given-names>SY</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Shi</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation</article-title><source>Cell</source><volume>159</volume><fpage>558</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.09.049</pub-id><pub-id pub-id-type="pmid">25417107</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Durbin</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title><source>Bioinformatics</source><volume>25</volume><fpage>1754</fpage><lpage>1760</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp324</pub-id><pub-id pub-id-type="pmid">19451168</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liedtke</surname> <given-names>M</given-names></name><name><surname>Ayton</surname> <given-names>PM</given-names></name><name><surname>Somervaille</surname> <given-names>TC</given-names></name><name><surname>Smith</surname> <given-names>KS</given-names></name><name><surname>Cleary</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Self-association mediated by the ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6</article-title><source>Blood</source><volume>116</volume><fpage>63</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-09-243386</pub-id><pub-id pub-id-type="pmid">20395419</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>C</given-names></name><name><surname>Smith</surname> <given-names>ER</given-names></name><name><surname>Takahashi</surname> <given-names>H</given-names></name><name><surname>Lai</surname> <given-names>KC</given-names></name><name><surname>Martin-Brown</surname> <given-names>S</given-names></name><name><surname>Florens</surname> <given-names>L</given-names></name><name><surname>Washburn</surname> <given-names>MP</given-names></name><name><surname>Conaway</surname> <given-names>JW</given-names></name><name><surname>Conaway</surname> <given-names>RC</given-names></name><name><surname>Shilatifard</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia</article-title><source>Molecular Cell</source><volume>37</volume><fpage>429</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.01.026</pub-id><pub-id pub-id-type="pmid">20159561</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname> <given-names>RT</given-names></name><name><surname>Lavau</surname> <given-names>C</given-names></name><name><surname>Du</surname> <given-names>C</given-names></name><name><surname>Simone</surname> <given-names>F</given-names></name><name><surname>Polak</surname> <given-names>PE</given-names></name><name><surname>Kawamata</surname> <given-names>S</given-names></name><name><surname>Thirman</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>5678</fpage><lpage>5687</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.16.5678-5687.2001</pub-id><pub-id pub-id-type="pmid">11463848</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacPherson</surname> <given-names>L</given-names></name><name><surname>Anokye</surname> <given-names>J</given-names></name><name><surname>Yeung</surname> <given-names>MM</given-names></name><name><surname>Lam</surname> <given-names>EYN</given-names></name><name><surname>Chan</surname> <given-names>YC</given-names></name><name><surname>Weng</surname> <given-names>CF</given-names></name><name><surname>Yeh</surname> <given-names>P</given-names></name><name><surname>Knezevic</surname> <given-names>K</given-names></name><name><surname>Butler</surname> <given-names>MS</given-names></name><name><surname>Hoegl</surname> <given-names>A</given-names></name><name><surname>Chan</surname> <given-names>KL</given-names></name><name><surname>Burr</surname> <given-names>ML</given-names></name><name><surname>Gearing</surname> <given-names>LJ</given-names></name><name><surname>Willson</surname> <given-names>T</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Choi</surname> <given-names>J</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Bilardi</surname> <given-names>RA</given-names></name><name><surname>Falk</surname> <given-names>H</given-names></name><name><surname>Nguyen</surname> <given-names>N</given-names></name><name><surname>Stupple</surname> <given-names>PA</given-names></name><name><surname>Peat</surname> <given-names>TS</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>de Silva</surname> <given-names>M</given-names></name><name><surname>Carrasco-Pozo</surname> <given-names>C</given-names></name><name><surname>Avery</surname> <given-names>VM</given-names></name><name><surname>Khoo</surname> <given-names>PS</given-names></name><name><surname>Dolezal</surname> <given-names>O</given-names></name><name><surname>Dennis</surname> <given-names>ML</given-names></name><name><surname>Nuttall</surname> <given-names>S</given-names></name><name><surname>Surjadi</surname> <given-names>R</given-names></name><name><surname>Newman</surname> <given-names>J</given-names></name><name><surname>Ren</surname> <given-names>B</given-names></name><name><surname>Leaver</surname> <given-names>DJ</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Baell</surname> <given-names>JB</given-names></name><name><surname>Dovey</surname> <given-names>O</given-names></name><name><surname>Vassiliou</surname> <given-names>GS</given-names></name><name><surname>Grebien</surname> <given-names>F</given-names></name><name><surname>Dawson</surname> <given-names>SJ</given-names></name><name><surname>Street</surname> <given-names>IP</given-names></name><name><surname>Monahan</surname> <given-names>BJ</given-names></name><name><surname>Burns</surname> <given-names>CJ</given-names></name><name><surname>Choudhary</surname> <given-names>C</given-names></name><name><surname>Blewitt</surname> <given-names>ME</given-names></name><name><surname>Voss</surname> <given-names>AK</given-names></name><name><surname>Thomas</surname> <given-names>T</given-names></name><name><surname>Dawson</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>HBO1 is required for the maintenance of leukaemia stem cells</article-title><source>Nature</source><volume>577</volume><fpage>266</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1835-6</pub-id><pub-id pub-id-type="pmid">31827282</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cutadapt removes adapter sequences from high-throughput sequencing reads</article-title><source>EMBnet.journal</source><volume>17</volume><fpage>10</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.14806/ej.17.1.200</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname> <given-names>C</given-names></name><name><surname>Burmeister</surname> <given-names>T</given-names></name><name><surname>Gröger</surname> <given-names>D</given-names></name><name><surname>Tsaur</surname> <given-names>G</given-names></name><name><surname>Fechina</surname> <given-names>L</given-names></name><name><surname>Renneville</surname> <given-names>A</given-names></name><name><surname>Sutton</surname> <given-names>R</given-names></name><name><surname>Venn</surname> <given-names>NC</given-names></name><name><surname>Emerenciano</surname> <given-names>M</given-names></name><name><surname>Pombo-de-Oliveira</surname> <given-names>MS</given-names></name><name><surname>Barbieri Blunck</surname> <given-names>C</given-names></name><name><surname>Almeida Lopes</surname> <given-names>B</given-names></name><name><surname>Zuna</surname> <given-names>J</given-names></name><name><surname>Trka</surname> <given-names>J</given-names></name><name><surname>Ballerini</surname> <given-names>P</given-names></name><name><surname>Lapillonne</surname> <given-names>H</given-names></name><name><surname>De Braekeleer</surname> <given-names>M</given-names></name><name><surname>Cazzaniga</surname> <given-names>G</given-names></name><name><surname>Corral Abascal</surname> <given-names>L</given-names></name><name><surname>van der Velden</surname> <given-names>VHJ</given-names></name><name><surname>Delabesse</surname> <given-names>E</given-names></name><name><surname>Park</surname> <given-names>TS</given-names></name><name><surname>Oh</surname> <given-names>SH</given-names></name><name><surname>Silva</surname> <given-names>MLM</given-names></name><name><surname>Lund-Aho</surname> <given-names>T</given-names></name><name><surname>Juvonen</surname> <given-names>V</given-names></name><name><surname>Moore</surname> <given-names>AS</given-names></name><name><surname>Heidenreich</surname> <given-names>O</given-names></name><name><surname>Vormoor</surname> <given-names>J</given-names></name><name><surname>Zerkalenkova</surname> <given-names>E</given-names></name><name><surname>Olshanskaya</surname> <given-names>Y</given-names></name><name><surname>Bueno</surname> <given-names>C</given-names></name><name><surname>Menendez</surname> <given-names>P</given-names></name><name><surname>Teigler-Schlegel</surname> <given-names>A</given-names></name><name><surname>Zur Stadt</surname> <given-names>U</given-names></name><name><surname>Lentes</surname> <given-names>J</given-names></name><name><surname>Göhring</surname> <given-names>G</given-names></name><name><surname>Kustanovich</surname> <given-names>A</given-names></name><name><surname>Aleinikova</surname> <given-names>O</given-names></name><name><surname>Schäfer</surname> <given-names>BW</given-names></name><name><surname>Kubetzko</surname> <given-names>S</given-names></name><name><surname>Madsen</surname> <given-names>HO</given-names></name><name><surname>Gruhn</surname> <given-names>B</given-names></name><name><surname>Duarte</surname> <given-names>X</given-names></name><name><surname>Gameiro</surname> <given-names>P</given-names></name><name><surname>Lippert</surname> <given-names>E</given-names></name><name><surname>Bidet</surname> <given-names>A</given-names></name><name><surname>Cayuela</surname> <given-names>JM</given-names></name><name><surname>Clappier</surname> <given-names>E</given-names></name><name><surname>Alonso</surname> <given-names>CN</given-names></name><name><surname>Zwaan</surname> <given-names>CM</given-names></name><name><surname>van den Heuvel-Eibrink</surname> <given-names>MM</given-names></name><name><surname>Izraeli</surname> <given-names>S</given-names></name><name><surname>Trakhtenbrot</surname> <given-names>L</given-names></name><name><surname>Archer</surname> <given-names>P</given-names></name><name><surname>Hancock</surname> <given-names>J</given-names></name><name><surname>Möricke</surname> <given-names>A</given-names></name><name><surname>Alten</surname> <given-names>J</given-names></name><name><surname>Schrappe</surname> <given-names>M</given-names></name><name><surname>Stanulla</surname> <given-names>M</given-names></name><name><surname>Strehl</surname> <given-names>S</given-names></name><name><surname>Attarbaschi</surname> <given-names>A</given-names></name><name><surname>Dworzak</surname> <given-names>M</given-names></name><name><surname>Haas</surname> <given-names>OA</given-names></name><name><surname>Panzer-Grümayer</surname> <given-names>R</given-names></name><name><surname>Sedék</surname> <given-names>L</given-names></name><name><surname>Szczepański</surname> <given-names>T</given-names></name><name><surname>Caye</surname> <given-names>A</given-names></name><name><surname>Suarez</surname> <given-names>L</given-names></name><name><surname>Cavé</surname> <given-names>H</given-names></name><name><surname>Marschalek</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The MLL recombinome of acute leukemias in 2017</article-title><source>Leukemia</source><volume>32</volume><fpage>273</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1038/leu.2017.213</pub-id><pub-id pub-id-type="pmid">28701730</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname> <given-names>TA</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>GG</given-names></name><name><surname>Stadler</surname> <given-names>SC</given-names></name><name><surname>Basrur</surname> <given-names>V</given-names></name><name><surname>Whitcomb</surname> <given-names>SJ</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Ruthenburg</surname> <given-names>AJ</given-names></name><name><surname>Elenitoba-Johnson</surname> <given-names>KS</given-names></name><name><surname>Roeder</surname> <given-names>RG</given-names></name><name><surname>Allis</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis</article-title><source>Molecular Cell</source><volume>38</volume><fpage>853</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.05.011</pub-id><pub-id pub-id-type="pmid">20541448</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishima</surname> <given-names>Y</given-names></name><name><surname>Miyagi</surname> <given-names>S</given-names></name><name><surname>Saraya</surname> <given-names>A</given-names></name><name><surname>Negishi</surname> <given-names>M</given-names></name><name><surname>Endoh</surname> <given-names>M</given-names></name><name><surname>Endo</surname> <given-names>TA</given-names></name><name><surname>Toyoda</surname> <given-names>T</given-names></name><name><surname>Shinga</surname> <given-names>J</given-names></name><name><surname>Katsumoto</surname> <given-names>T</given-names></name><name><surname>Chiba</surname> <given-names>T</given-names></name><name><surname>Yamaguchi</surname> <given-names>N</given-names></name><name><surname>Kitabayashi</surname> <given-names>I</given-names></name><name><surname>Koseki</surname> <given-names>H</given-names></name><name><surname>Iwama</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis</article-title><source>Blood</source><volume>118</volume><fpage>2443</fpage><lpage>2453</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-01-331892</pub-id><pub-id pub-id-type="pmid">21753189</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname> <given-names>R</given-names></name><name><surname>Okuda</surname> <given-names>H</given-names></name><name><surname>Kanai</surname> <given-names>A</given-names></name><name><surname>Takahashi</surname> <given-names>S</given-names></name><name><surname>Kawamura</surname> <given-names>T</given-names></name><name><surname>Matsui</surname> <given-names>H</given-names></name><name><surname>Kitamura</surname> <given-names>T</given-names></name><name><surname>Kitabayashi</surname> <given-names>I</given-names></name><name><surname>Inaba</surname> <given-names>T</given-names></name><name><surname>Yokoyama</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Activation of CpG-Rich promoters mediated by MLL drives MOZ-Rearranged leukemia</article-title><source>Cell Reports</source><volume>32</volume><elocation-id>108200</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108200</pub-id><pub-id pub-id-type="pmid">32997997</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname> <given-names>R</given-names></name><name><surname>Yokoyama</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Protocol for fractionation-assisted native ChIP (fanChIP) to capture protein-protein/DNA interactions on chromatin</article-title><source>STAR Protocols</source><volume>2</volume><elocation-id>100404</elocation-id><pub-id pub-id-type="doi">10.1016/j.xpro.2021.100404</pub-id><pub-id pub-id-type="pmid">33855306</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname> <given-names>S</given-names></name><name><surname>Kojima</surname> <given-names>T</given-names></name><name><surname>Kitamura</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Plat-E: an efficient and stable system for transient packaging of retroviruses</article-title><source>Gene Therapy</source><volume>7</volume><fpage>1063</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3301206</pub-id><pub-id pub-id-type="pmid">10871756</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagase</surname> <given-names>T</given-names></name><name><surname>Yamakawa</surname> <given-names>H</given-names></name><name><surname>Tadokoro</surname> <given-names>S</given-names></name><name><surname>Nakajima</surname> <given-names>D</given-names></name><name><surname>Inoue</surname> <given-names>S</given-names></name><name><surname>Yamaguchi</surname> <given-names>K</given-names></name><name><surname>Itokawa</surname> <given-names>Y</given-names></name><name><surname>Kikuno</surname> <given-names>RF</given-names></name><name><surname>Koga</surname> <given-names>H</given-names></name><name><surname>Ohara</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Exploration of human ORFeome: high-throughput preparation of ORF clones and efficient characterization of their protein products</article-title><source>DNA Research</source><volume>15</volume><fpage>137</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1093/dnares/dsn004</pub-id><pub-id pub-id-type="pmid">18316326</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname> <given-names>H</given-names></name><name><surname>Kawaguchi</surname> <given-names>M</given-names></name><name><surname>Kanai</surname> <given-names>A</given-names></name><name><surname>Matsui</surname> <given-names>H</given-names></name><name><surname>Kawamura</surname> <given-names>T</given-names></name><name><surname>Inaba</surname> <given-names>T</given-names></name><name><surname>Kitabayashi</surname> <given-names>I</given-names></name><name><surname>Yokoyama</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MLL fusion proteins link transcriptional coactivators to previously active CpG-rich promoters</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>4241</fpage><lpage>4256</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1394</pub-id><pub-id pub-id-type="pmid">24465000</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname> <given-names>H</given-names></name><name><surname>Kanai</surname> <given-names>A</given-names></name><name><surname>Ito</surname> <given-names>S</given-names></name><name><surname>Matsui</surname> <given-names>H</given-names></name><name><surname>Yokoyama</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>AF4 uses the SL1 components of RNAP1 machinery to initiate MLL fusion- and AEP-dependent transcription</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>8869</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms9869</pub-id><pub-id pub-id-type="pmid">26593443</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname> <given-names>H</given-names></name><name><surname>Takahashi</surname> <given-names>S</given-names></name><name><surname>Takaori-Kondo</surname> <given-names>A</given-names></name><name><surname>Yokoyama</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TBP loading by AF4 through SL1 is the major rate-limiting step in MLL fusion-dependent transcription</article-title><source>Cell Cycle</source><volume>15</volume><fpage>2712</fpage><lpage>2722</lpage><pub-id pub-id-type="doi">10.1080/15384101.2016.1222337</pub-id><pub-id pub-id-type="pmid">27564129</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname> <given-names>H</given-names></name><name><surname>Stanojevic</surname> <given-names>B</given-names></name><name><surname>Kanai</surname> <given-names>A</given-names></name><name><surname>Kawamura</surname> <given-names>T</given-names></name><name><surname>Takahashi</surname> <given-names>S</given-names></name><name><surname>Matsui</surname> <given-names>H</given-names></name><name><surname>Takaori-Kondo</surname> <given-names>A</given-names></name><name><surname>Yokoyama</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia</article-title><source>Journal of Clinical Investigation</source><volume>127</volume><fpage>1918</fpage><lpage>1931</lpage><pub-id pub-id-type="doi">10.1172/JCI91406</pub-id><pub-id pub-id-type="pmid">28394257</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname> <given-names>H</given-names></name><name><surname>Yokoyama</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>In vivo leukemogenesis model using retrovirus transduction</article-title><source>Bio-Protocol</source><volume>7</volume><elocation-id>BioProtoc.2627</elocation-id><pub-id pub-id-type="doi">10.21769/BioProtoc.2627</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname> <given-names>H</given-names></name><name><surname>Yokoyama</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Myeloid progenitor transformation assay</article-title><source>Bio-Protocol</source><volume>7</volume><elocation-id>BioProtoc.2626</elocation-id><pub-id pub-id-type="doi">10.21769/BioProtoc.2626</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradeepa</surname> <given-names>MM</given-names></name><name><surname>Sutherland</surname> <given-names>HG</given-names></name><name><surname>Ule</surname> <given-names>J</given-names></name><name><surname>Grimes</surname> <given-names>GR</given-names></name><name><surname>Bickmore</surname> <given-names>WA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Psip1/Ledgf p52 binds methylated histone H3K36 and splicing factors and contributes to the regulation of alternative splicing</article-title><source>PLOS Genetics</source><volume>8</volume><elocation-id>e1002717</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1002717</pub-id><pub-id pub-id-type="pmid">22615581</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Schulze-Gahmen</surname> <given-names>U</given-names></name><name><surname>Stjepanovic</surname> <given-names>G</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name><name><surname>Hurley</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structural basis for ELL2 and AFF4 activation of HIV-1 proviral transcription</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14076</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14076</pub-id><pub-id pub-id-type="pmid">28134250</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>A</given-names></name><name><surname>Murai</surname> <given-names>MJ</given-names></name><name><surname>He</surname> <given-names>S</given-names></name><name><surname>Lund</surname> <given-names>G</given-names></name><name><surname>Hartley</surname> <given-names>T</given-names></name><name><surname>Purohit</surname> <given-names>T</given-names></name><name><surname>Reddy</surname> <given-names>G</given-names></name><name><surname>Chruszcz</surname> <given-names>M</given-names></name><name><surname>Grembecka</surname> <given-names>J</given-names></name><name><surname>Cierpicki</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia</article-title><source>Blood</source><volume>120</volume><fpage>4461</fpage><lpage>4469</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-05-429274</pub-id><pub-id pub-id-type="pmid">22936661</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shilatifard</surname> <given-names>A</given-names></name><name><surname>Lane</surname> <given-names>WS</given-names></name><name><surname>Jackson</surname> <given-names>KW</given-names></name><name><surname>Conaway</surname> <given-names>RC</given-names></name><name><surname>Conaway</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>An RNA polymerase II elongation factor encoded by the human ELL gene</article-title><source>Science</source><volume>271</volume><fpage>1873</fpage><lpage>1876</lpage><pub-id pub-id-type="doi">10.1126/science.271.5257.1873</pub-id><pub-id pub-id-type="pmid">8596958</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shima</surname> <given-names>Y</given-names></name><name><surname>Yumoto</surname> <given-names>M</given-names></name><name><surname>Katsumoto</surname> <given-names>T</given-names></name><name><surname>Kitabayashi</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MLL is essential for NUP98-HOXA9-induced leukemia</article-title><source>Leukemia</source><volume>31</volume><fpage>2200</fpage><lpage>2210</lpage><pub-id pub-id-type="doi">10.1038/leu.2017.62</pub-id><pub-id pub-id-type="pmid">28210005</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simone</surname> <given-names>F</given-names></name><name><surname>Polak</surname> <given-names>PE</given-names></name><name><surname>Kaberlein</surname> <given-names>JJ</given-names></name><name><surname>Luo</surname> <given-names>RT</given-names></name><name><surname>Levitan</surname> <given-names>DA</given-names></name><name><surname>Thirman</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein</article-title><source>Blood</source><volume>98</volume><fpage>201</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1182/blood.V98.1.201</pub-id><pub-id pub-id-type="pmid">11418481</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simone</surname> <given-names>F</given-names></name><name><surname>Luo</surname> <given-names>RT</given-names></name><name><surname>Polak</surname> <given-names>PE</given-names></name><name><surname>Kaberlein</surname> <given-names>JJ</given-names></name><name><surname>Thirman</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties</article-title><source>Blood</source><volume>101</volume><fpage>2355</fpage><lpage>2362</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-06-1664</pub-id><pub-id pub-id-type="pmid">12446457</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname> <given-names>SA</given-names></name><name><surname>Dykxhoorn</surname> <given-names>DM</given-names></name><name><surname>Palliser</surname> <given-names>D</given-names></name><name><surname>Mizuno</surname> <given-names>H</given-names></name><name><surname>Yu</surname> <given-names>EY</given-names></name><name><surname>An</surname> <given-names>DS</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name><name><surname>Chen</surname> <given-names>IS</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name><name><surname>Sharp</surname> <given-names>PA</given-names></name><name><surname>Weinberg</surname> <given-names>RA</given-names></name><name><surname>Novina</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Lentivirus-delivered stable gene silencing by RNAi in primary cells</article-title><source>RNA</source><volume>9</volume><fpage>493</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1261/rna.2192803</pub-id><pub-id pub-id-type="pmid">12649500</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname> <given-names>H</given-names></name><name><surname>Parmely</surname> <given-names>TJ</given-names></name><name><surname>Sato</surname> <given-names>S</given-names></name><name><surname>Tomomori-Sato</surname> <given-names>C</given-names></name><name><surname>Banks</surname> <given-names>CA</given-names></name><name><surname>Kong</surname> <given-names>SE</given-names></name><name><surname>Szutorisz</surname> <given-names>H</given-names></name><name><surname>Swanson</surname> <given-names>SK</given-names></name><name><surname>Martin-Brown</surname> <given-names>S</given-names></name><name><surname>Washburn</surname> <given-names>MP</given-names></name><name><surname>Florens</surname> <given-names>L</given-names></name><name><surname>Seidel</surname> <given-names>CW</given-names></name><name><surname>Lin</surname> <given-names>C</given-names></name><name><surname>Smith</surname> <given-names>ER</given-names></name><name><surname>Shilatifard</surname> <given-names>A</given-names></name><name><surname>Conaway</surname> <given-names>RC</given-names></name><name><surname>Conaway</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Human mediator subunit MED26 functions as a docking site for transcription elongation factors</article-title><source>Cell</source><volume>146</volume><fpage>92</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.06.005</pub-id><pub-id pub-id-type="pmid">21729782</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname> <given-names>S</given-names></name><name><surname>Yokoyama</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The molecular functions of common and atypical MLL fusion protein complexes</article-title><source>Biochimica Et Biophysica Acta (BBA) - Gene Regulatory Mechanisms</source><volume>1863</volume><elocation-id>194548</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbagrm.2020.194548</pub-id><pub-id pub-id-type="pmid">32320750</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorvaldsdóttir</surname> <given-names>H</given-names></name><name><surname>Robinson</surname> <given-names>JT</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration</article-title><source>Briefings in Bioinformatics</source><volume>14</volume><fpage>178</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1093/bib/bbs017</pub-id><pub-id pub-id-type="pmid">22517427</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tkachuk</surname> <given-names>DC</given-names></name><name><surname>Kohler</surname> <given-names>S</given-names></name><name><surname>Cleary</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Involvement of a homolog of <italic>Drosophila</italic> trithorax by 11q23 chromosomal translocations in acute leukemias</article-title><source>Cell</source><volume>71</volume><fpage>691</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90602-9</pub-id><pub-id pub-id-type="pmid">1423624</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzelepis</surname> <given-names>K</given-names></name><name><surname>Koike-Yusa</surname> <given-names>H</given-names></name><name><surname>De Braekeleer</surname> <given-names>E</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Metzakopian</surname> <given-names>E</given-names></name><name><surname>Dovey</surname> <given-names>OM</given-names></name><name><surname>Mupo</surname> <given-names>A</given-names></name><name><surname>Grinkevich</surname> <given-names>V</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Mazan</surname> <given-names>M</given-names></name><name><surname>Gozdecka</surname> <given-names>M</given-names></name><name><surname>Ohnishi</surname> <given-names>S</given-names></name><name><surname>Cooper</surname> <given-names>J</given-names></name><name><surname>Patel</surname> <given-names>M</given-names></name><name><surname>McKerrell</surname> <given-names>T</given-names></name><name><surname>Chen</surname> <given-names>B</given-names></name><name><surname>Domingues</surname> <given-names>AF</given-names></name><name><surname>Gallipoli</surname> <given-names>P</given-names></name><name><surname>Teichmann</surname> <given-names>S</given-names></name><name><surname>Ponstingl</surname> <given-names>H</given-names></name><name><surname>McDermott</surname> <given-names>U</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>Huntly</surname> <given-names>BJP</given-names></name><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Pina</surname> <given-names>C</given-names></name><name><surname>Vassiliou</surname> <given-names>GS</given-names></name><name><surname>Yusa</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia</article-title><source>Cell Reports</source><volume>17</volume><fpage>1193</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.09.079</pub-id><pub-id pub-id-type="pmid">27760321</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Nuland</surname> <given-names>R</given-names></name><name><surname>van Schaik</surname> <given-names>FM</given-names></name><name><surname>Simonis</surname> <given-names>M</given-names></name><name><surname>van Heesch</surname> <given-names>S</given-names></name><name><surname>Cuppen</surname> <given-names>E</given-names></name><name><surname>Boelens</surname> <given-names>R</given-names></name><name><surname>Timmers</surname> <given-names>HM</given-names></name><name><surname>van Ingen</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Nucleosomal DNA binding drives the recognition of H3K36-methylated nucleosomes by the PSIP1-PWWP domain</article-title><source>Epigenetics &amp; Chromatin</source><volume>6</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.1186/1756-8935-6-12</pub-id><pub-id pub-id-type="pmid">23656834</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname> <given-names>L</given-names></name><name><surname>Wen</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Lyu</surname> <given-names>J</given-names></name><name><surname>Xi</surname> <given-names>Y</given-names></name><name><surname>Hoshii</surname> <given-names>T</given-names></name><name><surname>Joseph</surname> <given-names>JK</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Loh</surname> <given-names>YE</given-names></name><name><surname>Erb</surname> <given-names>MA</given-names></name><name><surname>Souza</surname> <given-names>AL</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name><name><surname>Shen</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Allis</surname> <given-names>CD</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name><name><surname>Shi</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia</article-title><source>Nature</source><volume>543</volume><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/nature21687</pub-id><pub-id pub-id-type="pmid">28241141</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>GG</given-names></name><name><surname>Cai</surname> <given-names>L</given-names></name><name><surname>Pasillas</surname> <given-names>MP</given-names></name><name><surname>Kamps</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis</article-title><source>Nature Cell Biology</source><volume>9</volume><fpage>804</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1038/ncb1608</pub-id><pub-id pub-id-type="pmid">17589499</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Song</surname> <given-names>J</given-names></name><name><surname>Milne</surname> <given-names>TA</given-names></name><name><surname>Wang</surname> <given-names>GG</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Allis</surname> <given-names>CD</given-names></name><name><surname>Patel</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression</article-title><source>Cell</source><volume>141</volume><fpage>1183</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.05.016</pub-id><pub-id pub-id-type="pmid">20541251</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiederschain</surname> <given-names>D</given-names></name><name><surname>Kawai</surname> <given-names>H</given-names></name><name><surname>Gu</surname> <given-names>J</given-names></name><name><surname>Shilatifard</surname> <given-names>A</given-names></name><name><surname>Yuan</surname> <given-names>ZM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL</article-title><source>Molecular and Cellular Biology</source><volume>23</volume><fpage>4230</fpage><lpage>4246</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.12.4230-4246.2003</pub-id><pub-id pub-id-type="pmid">12773566</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Valerio</surname> <given-names>DG</given-names></name><name><surname>Eisold</surname> <given-names>ME</given-names></name><name><surname>Sinha</surname> <given-names>A</given-names></name><name><surname>Koche</surname> <given-names>RP</given-names></name><name><surname>Hu</surname> <given-names>W</given-names></name><name><surname>Chen</surname> <given-names>CW</given-names></name><name><surname>Chu</surname> <given-names>SH</given-names></name><name><surname>Brien</surname> <given-names>GL</given-names></name><name><surname>Park</surname> <given-names>CY</given-names></name><name><surname>Hsieh</surname> <given-names>JJ</given-names></name><name><surname>Ernst</surname> <given-names>P</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>NUP98 fusion proteins interact with the NSL and MLL1 complexes to drive leukemogenesis</article-title><source>Cancer Cell</source><volume>30</volume><fpage>863</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.10.019</pub-id><pub-id pub-id-type="pmid">27889185</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname> <given-names>A</given-names></name><name><surname>Kitabayashi</surname> <given-names>I</given-names></name><name><surname>Ayton</surname> <given-names>PM</given-names></name><name><surname>Cleary</surname> <given-names>ML</given-names></name><name><surname>Ohki</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties</article-title><source>Blood</source><volume>100</volume><fpage>3710</fpage><lpage>3718</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-04-1015</pub-id><pub-id pub-id-type="pmid">12393701</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Wysocka</surname> <given-names>J</given-names></name><name><surname>Sanyal</surname> <given-names>M</given-names></name><name><surname>Aufiero</surname> <given-names>DJ</given-names></name><name><surname>Kitabayashi</surname> <given-names>I</given-names></name><name><surname>Herr</surname> <given-names>W</given-names></name><name><surname>Cleary</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with Menin to regulate hox gene expression</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>5639</fpage><lpage>5649</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.13.5639-5649.2004</pub-id><pub-id pub-id-type="pmid">15199122</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname> <given-names>A</given-names></name><name><surname>Somervaille</surname> <given-names>TC</given-names></name><name><surname>Smith</surname> <given-names>KS</given-names></name><name><surname>Rozenblatt-Rosen</surname> <given-names>O</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Cleary</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis</article-title><source>Cell</source><volume>123</volume><fpage>207</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.09.025</pub-id><pub-id pub-id-type="pmid">16239140</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname> <given-names>A</given-names></name><name><surname>Lin</surname> <given-names>M</given-names></name><name><surname>Naresh</surname> <given-names>A</given-names></name><name><surname>Kitabayashi</surname> <given-names>I</given-names></name><name><surname>Cleary</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription</article-title><source>Cancer Cell</source><volume>17</volume><fpage>198</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.12.040</pub-id><pub-id pub-id-type="pmid">20153263</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname> <given-names>A</given-names></name><name><surname>Cleary</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Menin critically links MLL proteins with LEDGF on cancer-associated target genes</article-title><source>Cancer Cell</source><volume>14</volume><fpage>36</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.05.003</pub-id><pub-id pub-id-type="pmid">18598942</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>BD</given-names></name><name><surname>Hanson</surname> <given-names>RD</given-names></name><name><surname>Hess</surname> <given-names>JL</given-names></name><name><surname>Horning</surname> <given-names>SE</given-names></name><name><surname>Korsmeyer</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis</article-title><source>PNAS</source><volume>95</volume><fpage>10632</fpage><lpage>10636</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.18.10632</pub-id><pub-id pub-id-type="pmid">9724755</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Gough</surname> <given-names>SM</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Vann</surname> <given-names>KR</given-names></name><name><surname>Li</surname> <given-names>K</given-names></name><name><surname>Cai</surname> <given-names>L</given-names></name><name><surname>Shi</surname> <given-names>X</given-names></name><name><surname>Aplan</surname> <given-names>PD</given-names></name><name><surname>Wang</surname> <given-names>GG</given-names></name><name><surname>Kutateladze</surname> <given-names>TG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanistic insights into chromatin targeting by leukemic NUP98-PHF23 fusion</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>3339</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17098-4</pub-id><pub-id pub-id-type="pmid">32620764</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><boxed-text><table-wrap id="keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or <break/>resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Other</td><td>MNase</td><td>Sigma-Aldrich</td><td>Cat#:N3755-200U</td><td/></tr><tr><td>Other</td><td>Protein-G Magnetic beads</td><td>Thermo Fisher Scientific</td><td>Cat#:1004D</td><td/></tr><tr><td>Other</td><td>FLAG M2 antibody-conjugated beads</td><td>Sigma-Aldrich</td><td>Cat#:M8823 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2637089">AB_2637089</ext-link></td><td/></tr><tr><td>Other</td><td>c-Kit magnetic beads</td><td>Miltenyi Biotec</td><td>Cat#:130-091-224 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2753213">AB_2753213</ext-link></td><td/></tr><tr><td>Other</td><td>MI-2–2</td><td>Calbiochem</td><td>Cat#:444825</td><td/></tr><tr><td>Other</td><td>WM1119</td><td>Enamine</td><td>Cat#:EN300-1719156</td><td/></tr><tr><td rowspan="2">Antibody</td><td rowspan="2">MLL(N)</td><td rowspan="2">Cell Signaling Technology</td><td rowspan="2">Cat#:14689 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2688009">AB_2688009</ext-link></td><td>WB(1000:1)</td></tr><tr><td>ChIP(1 μL/400 μL)</td></tr><tr><td>Antibody</td><td>MLL(N)</td><td>Generated in-house <xref ref-type="bibr" rid="bib61">Yokoyama et al., 2002</xref></td><td>rpN1</td><td>ChIP(1 μg/400 μL)</td></tr><tr><td>Antibody</td><td>MOZ</td><td>Active motif</td><td>Cat#:39868</td><td>ChIP(1 μg/400 μL)</td></tr><tr><td>Antibody</td><td>AF4</td><td>Santa Cruz Biotechnology</td><td>Cat#:sc-49350 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2226113">AB_2226113</ext-link></td><td>ChIP(1 μg/400 μL)</td></tr><tr><td>Antibody</td><td>TAF1C</td><td>Bethyl Laboratories</td><td>Cat#:A303-698A <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_11203194">AB_11203194</ext-link></td><td>ChIP(1 μg/400 μL)</td></tr><tr><td>Antibody</td><td>AF17</td><td>Bethyl Laboratories</td><td>Cat#:A302-198A <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1659777">AB_1659777</ext-link></td><td>ChIP(1 μg/400 μL)</td></tr><tr><td>Antibody</td><td>DOT1L</td><td>Bethyl Laboratories</td><td>Cat#:A300-953A <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_805775">AB_805775</ext-link></td><td>ChIP(1 μg/400 μL)</td></tr><tr><td>Antibody</td><td>CyclinT1</td><td>Santa Cruz Biotechnology</td><td>Cat#:sc-8127 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2073892">AB_2073892</ext-link></td><td>ChIP(1 μg/400 μL)</td></tr><tr><td rowspan="2">Antibody</td><td rowspan="2">ENL</td><td rowspan="2">Cell Signaling Technology</td><td rowspan="2">Cat#:14893S</td><td>WB(1000:1)</td></tr><tr><td>ChIP(5 μL/400 μL)</td></tr><tr><td>Antibody</td><td>Histone H3K4me3</td><td>Active motif</td><td>Cat#:39159 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2615077">AB_2615077</ext-link></td><td>ChIP(1 μg/400 μL)</td></tr><tr><td>Antibody</td><td>Histone H3K18ac</td><td>Abcam</td><td>Cat#:ab1191 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_298692">AB_298692</ext-link></td><td>ChIP(1 μg/400 μL)</td></tr><tr><td>Antibody</td><td>RNAP2 non-P</td><td>Abcam</td><td>8WG16/Cat#:ab817 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_306327">AB_306327</ext-link></td><td>ChIP(1 μg/400 μL)</td></tr><tr><td>Antibody</td><td>RNAP2 Ser5-P</td><td>Millipore</td><td>Cat#:05–623 <break/>AB_309852</td><td>ChIP(1 μg/400 μL)</td></tr><tr><td>Antibody</td><td>FLAG</td><td>Sigma-Aldrich</td><td>Cat#:F3165 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_259529">AB_259529</ext-link></td><td>ChIP(1 μg/400 μL)</td></tr><tr><td>Antibody</td><td>FLAG</td><td>Sigma-Aldrich</td><td>Cat#:F7425 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_439687">AB_439687</ext-link></td><td>WB(1000:1)</td></tr><tr><td rowspan="2">Antibody</td><td rowspan="2">HA</td><td rowspan="2">Roche</td><td rowspan="2">3F10/Cat#:11867423001 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_390918">AB_390918</ext-link></td><td>WB(1000:1)</td></tr><tr><td>ChIP(0.2 μg/400 μL)</td></tr><tr><td rowspan="2">Antibody</td><td rowspan="2">Xpress</td><td rowspan="2">Santa Cruz Biotechnology</td><td rowspan="2">Cat#:sc-7270 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_675763">AB_675763</ext-link></td><td>WB(1000:1)</td></tr><tr><td>ChIP(1 μg/400 μL)</td></tr><tr><td>Antibody</td><td>ELL</td><td>Cell Signaling Technology</td><td>Cat#:14468S <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2798489">AB_2798489</ext-link></td><td>WB(1000:1)</td></tr><tr><td rowspan="2">Antibody</td><td rowspan="2">HBO1</td><td rowspan="2">Abcam</td><td rowspan="2">Cat#:70183 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1269226">AB_1269226</ext-link></td><td>WB(1000:1)</td></tr><tr><td>ChIP(1 μg/400 μL)</td></tr><tr><td rowspan="2">Antibody</td><td rowspan="2">PHF16</td><td rowspan="2">Abcam</td><td rowspan="2">Cat#:129495 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_11157084">AB_11157084</ext-link></td><td>WB(1000:1)</td></tr><tr><td>ChIP(1 μg/400 μL)</td></tr><tr><td rowspan="2">Antibody</td><td rowspan="2">MEAF6</td><td rowspan="2">STJ</td><td rowspan="2">Cat#:116836</td><td>WB(1000:1)</td></tr><tr><td>ChIP(1 μg/400 μL)</td></tr><tr><td rowspan="2">Antibody</td><td rowspan="2">ING4</td><td rowspan="2">Abcam</td><td rowspan="2">Cat#:108621 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10860023">AB_10860023</ext-link></td><td>WB(1000:1)</td></tr><tr><td>ChIP(1 μg/400 μL)</td></tr><tr><td>Antibody</td><td>MLL(C)</td><td>Cell Signaling Technology</td><td>Cat#:14197S <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2688010">AB_2688010</ext-link></td><td>WB(1000:1)</td></tr><tr><td>Antibody</td><td>AF4</td><td>Bethyl Laboratories</td><td>Cat#:A302-344A <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1850255">AB_1850255</ext-link></td><td>WB(1000:1)</td></tr><tr><td>Antibody</td><td>AF5Q31</td><td>Bethyl Laboratories</td><td>Cat#:A302-538A <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1998985">AB_1998985</ext-link></td><td>WB(1000:1)</td></tr><tr><td>Antibody</td><td>P53</td><td>Santa Cruz Biotechnology</td><td>Cat#:sc-126 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_628082">AB_628082</ext-link></td><td>WB(1000:1)</td></tr><tr><td>Sequence-based reagent</td><td><italic>GAPDH</italic></td><td>Thermo Fisher Scientific</td><td>Hs02786624_g1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>HOXA9</italic></td><td>Thermo Fisher Scientific</td><td>Hs00365956_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>MYC</italic></td><td>Thermo Fisher Scientific</td><td>Hs01570247_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>RPL13A</italic></td><td>Thermo Fisher Scientific</td><td>Hs04194366_g1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>CDKN2C</italic></td><td>Thermo Fisher Scientific</td><td>Hs00176227_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Gapdh</italic></td><td>Thermo Fisher Scientific</td><td>Mm99999915_g1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Hoxa9</italic></td><td>Thermo Fisher Scientific</td><td>Mm00439364_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td><italic>Mllt1</italic></td><td>Thermo Fisher Scientific</td><td>Mm00452080_m1</td><td/></tr><tr><td>Sequence-based reagent</td><td>sgRNAs</td><td>This study</td><td/><td>See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref></td></tr><tr><td>Sequence-based reagent</td><td>Custom made qPCR primers</td><td>Thermo Fisher Scientific</td><td/><td>See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref></td></tr><tr><td>Recombinant DNA reagent</td><td>pMSCV-neo</td><td>Clontech</td><td>Cat#:634401</td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pLKO5.EFS.GFP</td><td>Addgene (gift from Benjamin Ebert) <xref ref-type="bibr" rid="bib14">Heckl et al., 2014</xref></td><td>Addgene #57822 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_57822">Addgene_57822</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pKLV2-Cas9.bsd</td><td>Addgene (gift from Kosuke Yusa) <xref ref-type="bibr" rid="bib54">Tzelepis et al., 2016</xref></td><td>Addgene #68343 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_68343">Addgene_68343</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pMDLg/pRRE</td><td>Addgene (gift from Didier Trono) <xref ref-type="bibr" rid="bib8">Dull et al., 1998</xref></td><td>Addgene #12251 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_12251">Addgene_12251</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pRSV-rev</td><td>Addgene (gift from Didier Trono) <xref ref-type="bibr" rid="bib8">Dull et al., 1998</xref></td><td>Addgene #12253 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_12253">Addgene_12253</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pMD2.G</td><td>Addgene (gift from Didier Trono) <xref ref-type="bibr" rid="bib8">Dull et al., 1998</xref></td><td>Addgene #12259 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_12259">Addgene_12259</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pLKO.1-puro</td><td>Addgene (gift from Bob Weinberg) <xref ref-type="bibr" rid="bib49">Stewart et al., 2003</xref></td><td>Addgene #8453 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_84530">Addgene_84530</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pLKO.1-sh-<italic>Mllt1</italic>-puro</td><td>GE Healthcare</td><td>TRCN0000084405</td><td/></tr><tr><td>Software, algorithm</td><td>GraphPad Prism7</td><td>GraphPad Software Inc</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td>Integrative Genomics Viewer</td><td><xref ref-type="bibr" rid="bib52">Thorvaldsdóttir et al., 2013</xref></td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_011793">SCR_011793</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td>Cutadapt</td><td><xref ref-type="bibr" rid="bib28">Martin, 2011</xref></td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_011841">SCR_011841</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td>BWA</td><td><xref ref-type="bibr" rid="bib23">Li and Durbin, 2009</xref></td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_010910">SCR_010910</ext-link></td><td/></tr><tr><td>Cell line (<italic>Homo sapiens</italic>)</td><td>Human: HEK293T</td><td>Gift from Michael Cleary</td><td/><td>Authenticated by JCRB Cell Bank in 2019</td></tr><tr><td>Cell line (<italic>Homo sapiens</italic>)</td><td>Human: HB1119</td><td>Gift from Michael Cleary <xref ref-type="bibr" rid="bib53">Tkachuk et al., 1992</xref></td><td/><td>The cell line was verified by the expression of MLL-ENL</td></tr><tr><td>Cell line (<italic>Homo sapiens</italic>)</td><td>Human: REH</td><td>Gift from Michael Cleary <xref ref-type="bibr" rid="bib62">Yokoyama et al., 2004</xref></td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_1650">CVCL_1650</ext-link></td><td>Authenticated by JCRB Cell Bank in 2021</td></tr><tr><td>Cell line (<italic>Homo sapiens</italic>)</td><td>Human: PLAT-E</td><td>Gift from Toshio Kitamura <xref ref-type="bibr" rid="bib34">Morita et al., 2000</xref></td><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_B488">CVCL_B488</ext-link></td><td/></tr><tr><td rowspan="2">Cell line (<italic>Homo sapiens</italic>)</td><td rowspan="2">Human: HEK293TN</td><td rowspan="2">System Bioscience</td><td>Cat#:LV900A-1</td><td rowspan="2"/></tr><tr><td>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_UL49">CVCL_UL49</ext-link></td></tr><tr><td>Cell line (<italic>Homo sapiens</italic>)</td><td>Human: HEK293T dMLLc3</td><td>Generated in-house <xref ref-type="bibr" rid="bib32">Miyamoto et al., 2020</xref></td><td/><td/></tr><tr><td>Cell line (<italic>Homo sapiens</italic>)</td><td>Human: HEK293T dMLLc7</td><td>Generated in-house <xref ref-type="bibr" rid="bib32">Miyamoto et al., 2020</xref></td><td/><td/></tr><tr><td>Cell line (<italic>Homo sapiens</italic>)</td><td>Human: HEK293TL</td><td>Generated in-house <xref ref-type="bibr" rid="bib37">Okuda et al., 2015</xref></td><td/><td/></tr><tr><td>Strain, strain background (<italic>Mus musculus</italic>)</td><td>Mouse: C57BL/6J</td><td>CLEA Japan</td><td/><td/></tr></tbody></table></table-wrap></boxed-text></app></app-group></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65872.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Shi</surname><given-names>Xiaobing</given-names></name><role>Reviewing Editor</role><aff><institution>Van Andel Institute</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Shi</surname><given-names>Xiaobing</given-names> </name><role>Reviewer</role><aff><institution>Van Andel Institute</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.01.08.425834">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.01.08.425834v1.full">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This is a quite comprehensive study demonstrating that various MLL fusions transform hematopoietic progenitors via HBO1-MLL interaction. The additional data provided in the revised manuscript have addressed most prior questions. This study adds mechanistic depth into the important recent discovery of HBO1 functions in MLL-fusion leukemias and provides potentially new therapeutic approach.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;HBO1-MLL interaction promotes AF4/ENL/P-TEFb-mediated leukemogenesis&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Xiaobing Shi as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Kevin Struhl as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>The manuscript by Takahashi et al., describes the interaction between MLL fusion proteins with HBO1 and its role in leukemogenesis. Myeloid progenitor transformation assays using various MLL fusion proteins reveal that MLL fusion proteins requires the TRX2 domain of MLL for effective leukemic transformation. IP-MS identifies HBO1 as a bona fide binding partner of the MLL TRX2 domain. ChIP-seq experiments in various cancer cell lines indicate overlap between MLL and some of the HBO complex subunits, however this does not establish recruitment at these sites. ChIP-qPCR at a few MLL-fusion target genes with MLL depletion supports the recruitment hypothesis somewhat although with only mixed and modest effect sizes. At this point the paper shifts to a seemingly distinct line of inquiry, which is not closely related to the HBO1-TRX2 story to the first three figures. The new direction examines the ELL fusion partner in some detail using similar fusion protein chimeras, but a portion of Figure 4, is largely confirmatory of previously established findings about the critical regions of ELL for transformation and its AF4/EAF1 partners, adding only that portions of the MLL fusion protein are dispensable, provided that they are replaced with the PWWP of LEDGF. Further experiments define potentially two distinct complexes that have already been characterized being recruited by ELL, although there is overlap here again with their previous studies, and the results are a little hard to interpret. The last figure in the paper tackles the seemingly unrelated Nup98-HBO1 fusion, a rare patient mutation-they demonstrate a requirement for MLL for viability of hematopoietic progenitors transformed by this fusion, connecting back to the TRX2 interaction, and show that Menin inhibitors slow growth.</p><p>Overall, this is a quite comprehensive study demonstrating that various MLL fusions transform hematopoietic progenitors via HBO1-MLL interaction. The quality of the science fairly high (with a few noted exceptions that can be addressed), but the lack of clarity in presentation actively obscures really nice and seemingly important elements of this work. It also stops short of really demonstrating that the MLL-TRX2 motif recruits HBO1 in some direct way, which would be of high impact if it could be more clearly molecularly defined.</p><p>1. The most significant impact of this manuscript is the identification of the TRX2 region of the MLL-N protein as the major point of contact (perhaps not direct), to the HBO1 complex, which adds mechanistic depth to the important recent discovery that the MLL-fusion leukemias rely on HBO1 function (MacPherson et al., Nature 2020). However, it is not clear whether this interaction is direct, or bridged by some, as yet unidentified factor including DNA. It is also important to define the point of contact on the HBO1 side (even which subunit).</p><p>2. The current evidence does not conclusively demonstrate that The MLL-HBO1 interaction is the mechanism of HBO1 recruitment. It would be helpful to do a ChIP experiment in the MLL null background rescuing with +/- TRX2 to demonstrate that this &quot;domain&quot; is responsible for the recruitment-- even more ideal, but perhaps beyond the scope would be a point-mutant that disrupts direct contact to the HBO1 complex.</p><p>3. A large number of ChIP-seq and RNA-seq are performed. However, it is not clear how many repeats were performed. This need to be clearly stated, and biological repeats are needed for at least some of the essential ones, such as MLL1, HBO1 and H3K14ac, the mark deposited by HBO1. It is also important to describe clearly the source and specificity of the antibodies used for ChIP.</p><p>4. It seems that characterization of the AF4 and EAF1 associated complexes (in Figures 4-6) is unrelated to the main topic of this paper. This part is essentially a reinterpretation of prior results from Okuda, JCI 2017. This portion of the prior paper should be corrected there.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65872.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisons:</p><p>1. The most significant impact of this manuscript is the identification of the TRX2 region of the MLL-N protein as the major point of contact (perhaps not direct), to the HBO1 complex, which adds mechanistic depth to the important recent discovery that the MLL-fusion leukemias rely on HBO1 function (MacPherson et al., Nature 2020). However, it is not clear whether this interaction is direct, or bridged by some, as yet unidentified factor including DNA. It is also important to define the point of contact on the HBO1 side (even which subunit).</p></disp-quote><p>To determine the major points of contact, we performed an immunoprecipitation followed by western blotting (IP-WB) analysis of the chromatin fractions from HEK293T cells transiently expressing various components of the HBO1 complex and the MLL bait protein (Figure 8). When each HBO1 complex component was co-expressed with the MLL bait protein, PHF16 and ING5 were weakly detected in the coprecipitates of the MLL bait protein, whereas HBO1 and MEAF6 were not (Figure 8A), suggesting that PHF16 and ING5 provide major points of contact for MLL. When all of the HBO complex components were co-expressed with the MLL bait protein, a very strong association was observed (Figure 8A, see fMLL 869/1124 + HBO1 complex), suggesting that MLL associates with the HBO1 complex through multiple contacts. Next, we omitted one component each from the HBO1 complex and tested which component provides the most significant contact for MLL. Omission of PHF16 or ING5 resulted in a drastic decrease of MLL-HBO1 complex association (Figure 8B), supporting the notion that PHF16 and ING5 provide major points of contact. Indeed, NUP98-ING5 fusion co-IPed MLL more efficiently compared to NUP98-HBO1 and NUP98-MEAF6 (Figure 7D). To further narrow down the structures responsible for MLL-HBO complex interaction, we generated a series of ING5 mutants and tested their association with MLL. Deleting the ING domain from ING5 resulted in the loss of MLL interaction (Figure 8C). In addition, mutations in the aromatic cage of the PHD finger of ING5, which is critical for methylation-specific association with Histone H3K4, also resulted in the loss of MLL interaction. This suggests that ING5 needs to be bound to methylated histone H3K4 and possibly mediates direct interaction with MLL via its ING domain. These results indicate that MLL-HBO1 complex interaction is mediated by multiple points of contact mainly mediated by PHF16 and ING5 in the chromatin-bound form. These new observations/notions have been added to the revised manuscript. Overall, our results indicated that MLL-HBO1 complex formation is highly context-dependent, which preferentially occurs on chromatin as a fully assembled HBO1 complex. As DNAseI treatment did not hinder the interaction, we believe that DNA is not required for MLL-HBO1 interaction (Figure 2—figure supplement 2B).</p><disp-quote content-type="editor-comment"><p>2. The current evidence does not conclusively demonstrate that The MLL-HBO1 interaction is the mechanism of HBO1 recruitment. It would be helpful to do a ChIP experiment in the MLL null background rescuing with +/- TRX2 to demonstrate that this &quot;domain&quot; is responsible for the recruitment-- even more ideal, but perhaps beyond the scope would be a point-mutant that disrupts direct contact to the HBO1 complex.</p></disp-quote><p>We have provided ChIP-qPCR analysis data of HEK293T cells lacking MLL (Figure 3F). We performed ChIP for HBO1 using 3 biological replicates and observed a consistent decrease in the HBO1 ChIP signals at the MYC promoter, supporting the idea that MLL-HBO1 interaction is the mechanism of HBO1 recruitment, at least partially, at the MYC promoter. However, it is also true that HBO1 is recruited to other non-MYC promoters such as RPL13A in the absence of MLL, indicating that HBO1 is recruited to the promoter in non-MLL-mediated manners as well. H3K4me3 marks were substantially decreased at the MYC promoter but not at the RPL13A promoter in MLL-deficient cells. This suggested that MLL-mediated H3K4 methylation is required for ING4/5-mediated HBO1 complex recruitment. As advised by the reviewer, we examined the ability of MLL mutants, with or without THD2 (Formally termed as TRX2 domain), to recruit HBO1 in MLL null background. We did not observe any substantial increase of HBO1 recruitment by the THD2-containing MLL mutant (Figure 3—figure supplement 1C), indicating that THD2 is not sufficient for HBO1 recruitment but requires the pre-existing H3K4me3 marks. We think that the MLL-HBO1 interaction enhances the recruitment of HBO1 to certain promoters such as MYC, while the HBO1 can be recruited to promoters in other ways. We speculate that gene promoters which depend on the AEP/SL1-mediated transcriptional pathway are heavily dependent on the MLL-HBO1 complex. In accord, the MYC promoter shows a relatively robust decrease of the ChIP signals of AEP/SL1 (i.e., ENL, CCNT1, CDK9 and TAF1C) in MLL knockout cells (Figure 3 and Figure 3—figure supplement1B). In the revised manuscript, we have added these new findings and modified the text to avoid giving the misleading impression that MLL is the sole element whose presence is sufficient for the HBO1 complex recruitment.</p><disp-quote content-type="editor-comment"><p>3. A large number of ChIP-seq and RNA-seq are performed. However, it is not clear how many repeats were performed. This need to be clearly stated, and biological repeats are needed for at least some of the essential ones, such as MLL1, HBO1 and H3K14ac, the mark deposited by HBO1. It is also important to describe clearly the source and specificity of the antibodies used for ChIP.</p></disp-quote><p>We have performed ChIP-seq analyses of MLL (MLL1) and HBO1complex in duplicates and deposited in the public archive. ChIP-seq data of H3K14ac was not presented in the initial manuscript. The HBO1/BRPF2 complex was shown to be responsible for the global acetylation of H3K14ac in the hematopoietic cells (1). However, it is considered that the preferred histone modifications provided by the HBO1/PHF16 complex are histone H4K5/8/12 acetylations rather than H3K14/23 acetylations (2). We apologize for indicating that the HBO1/PHF16 complex provides H3K14ac marks in the cartoon in the previous manuscript, which was incorrect. Thus, PHF16-, MEAF6-, and ING4-ChIP analyses were performed to more clearly demonstrate the specific localization of the HBO1 complex and the results have been presented. Details of the antibodies used for ChIP experiments are described in the revised manuscript in Key resource table.</p><disp-quote content-type="editor-comment"><p>4. It seems that characterization of the AF4 and EAF1 associated complexes (in Figures 4-6) is unrelated to the main topic of this paper. This part is essentially a reinterpretation of prior results from Okuda, JCI 2017. This portion of the prior paper should be corrected there.</p></disp-quote><p>The main focus of this study was understanding the role of the HBO1 complex in MLL-mediated transactivation pathways. The structure/function analysis of MLL fusion proteins demonstrated that MLL-ELL is highly dependent on the HBO1-mediated function in leukemic transformation. Hence, it was important to clarify the mechanism of gene activation by MLL-ELL in this paper to understand why HBO1 association is critically required for MLL-ELL-mediated transformation. Because MLL-ELL associates with AEP similarly to other major MLL fusions such as MLL-AF4 and MLL-ENL, it was speculated that MLL-ELL also activates its target genes via AEP. However, ELL associates with EAF family proteins and MLL-EAF also has transforming ability (3), which contradicts this idea. Thus, EAF1-mediated function could be more important for MLL-ELL-mediated transformation. To dissect the molecular mechanism of transformation, we generated a point mutant that selectively impaired ELL-EAF interaction and demonstrated that EAF1-association is dispensable for MLL-ELL-mediated transformation (Figure 6), thereby indicating that MLL-ELL transforms via AEP-mediated functions, which demands HBO1-mediated functions. We also showed that the presence of THD2 enhances ELL-AEP association to further suggest that one of the roles for the HBO1 complex is to enhance the association of ELL with AEP. These findings are not reinterpretations of our prior results and are relevant to the main topic of this paper, and therefore we have retained them in the revised manuscript.</p></body></sub-article></article>